NO309472B1 - Kinazolin-derivater, anvendelse og fremstilling derav, samt farmasöytisk preparat - Google Patents
Kinazolin-derivater, anvendelse og fremstilling derav, samt farmasöytisk preparat Download PDFInfo
- Publication number
- NO309472B1 NO309472B1 NO974940A NO974940A NO309472B1 NO 309472 B1 NO309472 B1 NO 309472B1 NO 974940 A NO974940 A NO 974940A NO 974940 A NO974940 A NO 974940A NO 309472 B1 NO309472 B1 NO 309472B1
- Authority
- NO
- Norway
- Prior art keywords
- formula
- chloro
- quinazoline
- pharmaceutically acceptable
- quinazoline derivative
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 12
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 5
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title description 2
- 150000003246 quinazolines Chemical class 0.000 claims description 59
- -1 2-dimethylaminoethoxy, 2-diethylaminoethoxy, 3-dimethylaminopropoxy, 3-diethylaminopropoxy, 2-(pyrrolidin-1-yl)ethoxy, 3-(pyrrolidin-1-yl)propoxy Chemical group 0.000 claims description 53
- 150000001875 compounds Chemical class 0.000 claims description 49
- 150000003839 salts Chemical class 0.000 claims description 41
- 125000003545 alkoxy group Chemical group 0.000 claims description 36
- 239000002253 acid Substances 0.000 claims description 24
- 230000001028 anti-proliverative effect Effects 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical group C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 5
- 238000007796 conventional method Methods 0.000 claims description 5
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 4
- STNFCUFBMSVMBL-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(2-morpholin-4-ylethoxy)quinazolin-4-amine Chemical group C=12C=C(OCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 STNFCUFBMSVMBL-UHFFFAOYSA-N 0.000 claims description 4
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 3
- BLFAAYGECSULMU-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(2-pyrrolidin-1-ylethoxy)quinazolin-4-amine Chemical group C=12C=C(OCCN3CCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 BLFAAYGECSULMU-UHFFFAOYSA-N 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 3
- 230000029936 alkylation Effects 0.000 claims description 2
- 238000005804 alkylation reaction Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- JACDFLVHUYYSBS-UHFFFAOYSA-N n-(3,4-difluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine Chemical group C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(F)=C1 JACDFLVHUYYSBS-UHFFFAOYSA-N 0.000 claims description 2
- JJKSOLDGGFGXJF-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-6-[3-(diethylamino)propoxy]-7-methoxyquinazolin-4-amine Chemical group N1=CN=C2C=C(OC)C(OCCCN(CC)CC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 JJKSOLDGGFGXJF-UHFFFAOYSA-N 0.000 claims description 2
- BQTOLZHBHCEHJX-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-6-[3-(dimethylamino)propoxy]-7-methoxyquinazolin-4-amine Chemical group C=12C=C(OCCCN(C)C)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 BQTOLZHBHCEHJX-UHFFFAOYSA-N 0.000 claims description 2
- IFIRBZOPPUFQRQ-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-piperidin-1-ylpropoxy)quinazolin-4-amine Chemical group C=12C=C(OCCCN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 IFIRBZOPPUFQRQ-UHFFFAOYSA-N 0.000 claims description 2
- XGPAXWVNLWKLEF-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical group C=12C=C(OCCCN3CCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGPAXWVNLWKLEF-UHFFFAOYSA-N 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 129
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 93
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 81
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 59
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 48
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 42
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 42
- 239000000243 solution Substances 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 32
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 32
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 31
- 206010028980 Neoplasm Diseases 0.000 description 29
- 238000000921 elemental analysis Methods 0.000 description 29
- 238000012360 testing method Methods 0.000 description 26
- 238000004440 column chromatography Methods 0.000 description 25
- 239000003480 eluent Substances 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 229910000027 potassium carbonate Inorganic materials 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 20
- 239000000463 material Substances 0.000 description 20
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- JLVTVCRXFMLUIF-UHFFFAOYSA-N O-Desmorpholinopropyl Gefitinib Chemical compound C=12C=C(O)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 JLVTVCRXFMLUIF-UHFFFAOYSA-N 0.000 description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 14
- 101800003838 Epidermal growth factor Proteins 0.000 description 13
- 241000282414 Homo sapiens Species 0.000 description 13
- 229940116977 epidermal growth factor Drugs 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 102400001368 Epidermal growth factor Human genes 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 239000007858 starting material Substances 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 7
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 102000001301 EGF receptor Human genes 0.000 description 6
- 108060006698 EGF receptor Proteins 0.000 description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000032823 cell division Effects 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- CZORGPPUWMSETM-UHFFFAOYSA-N 4-(3,4-difluoroanilino)-7-methoxyquinazolin-6-ol Chemical compound C=12C=C(O)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(F)=C1 CZORGPPUWMSETM-UHFFFAOYSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 201000004681 Psoriasis Diseases 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- DSYIUUXIRMLRQU-UHFFFAOYSA-N (4-chloro-7-methoxyquinazolin-6-yl) acetate;hydrochloride Chemical compound Cl.C1=NC(Cl)=C2C=C(OC(C)=O)C(OC)=CC2=N1 DSYIUUXIRMLRQU-UHFFFAOYSA-N 0.000 description 3
- SOLQIFINSOHAQD-UHFFFAOYSA-N (7-methoxy-4-oxo-1h-quinazolin-6-yl) acetate Chemical compound N1C=NC(=O)C2=C1C=C(OC)C(OC(C)=O)=C2 SOLQIFINSOHAQD-UHFFFAOYSA-N 0.000 description 3
- ALIORLVEFABXRY-UHFFFAOYSA-N 1-(3-chloropropyl)imidazole Chemical compound ClCCCN1C=CN=C1 ALIORLVEFABXRY-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- LJQNMDZRCXJETK-UHFFFAOYSA-N 3-chloro-n,n-dimethylpropan-1-amine;hydron;chloride Chemical compound Cl.CN(C)CCCCl LJQNMDZRCXJETK-UHFFFAOYSA-N 0.000 description 3
- BPDYNSGBOYVXBT-UHFFFAOYSA-N 4-(2,4-difluoroanilino)-7-methoxyquinazolin-6-ol Chemical compound C=12C=C(O)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C=C1F BPDYNSGBOYVXBT-UHFFFAOYSA-N 0.000 description 3
- PIAZYBLGBSMNLX-UHFFFAOYSA-N 4-(3-chloropropyl)morpholine Chemical compound ClCCCN1CCOCC1 PIAZYBLGBSMNLX-UHFFFAOYSA-N 0.000 description 3
- VFOPWDOJVKKSOP-UHFFFAOYSA-N 6-(3-bromopropoxy)-n-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine Chemical compound C=12C=C(OCCCBr)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 VFOPWDOJVKKSOP-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- IBZKBSXREAQDTO-UHFFFAOYSA-N 2-methoxy-n-(2-methoxyethyl)ethanamine Chemical compound COCCNCCOC IBZKBSXREAQDTO-UHFFFAOYSA-N 0.000 description 2
- RBHLFWNKEWLHBP-UHFFFAOYSA-N 4-(4-aminophenyl)butanoic acid Chemical compound NC1=CC=C(CCCC(O)=O)C=C1 RBHLFWNKEWLHBP-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- KOBGVRFQJWPUFX-UHFFFAOYSA-N 6-(2-bromoethoxy)-n-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine Chemical compound C=12C=C(OCCBr)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 KOBGVRFQJWPUFX-UHFFFAOYSA-N 0.000 description 2
- OKZIRNNFVQCDSA-UHFFFAOYSA-N 6-hydroxy-7-methoxy-1h-quinazolin-4-one Chemical compound C1=NC(O)=C2C=C(O)C(OC)=CC2=N1 OKZIRNNFVQCDSA-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 238000011717 athymic nude mouse Methods 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- XXBDUYQPZRPNMB-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-6-(2-imidazol-1-ylethoxy)-7-methoxyquinazolin-4-amine Chemical compound C=12C=C(OCCN3C=NC=C3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XXBDUYQPZRPNMB-UHFFFAOYSA-N 0.000 description 2
- WZAKDDWPQKWRTD-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(oxiran-2-ylmethoxy)quinazolin-4-amine Chemical compound C=12C=C(OCC3OC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 WZAKDDWPQKWRTD-UHFFFAOYSA-N 0.000 description 2
- MTSNDBYBIZSILH-UHFFFAOYSA-N n-phenylquinazolin-4-amine Chemical class N=1C=NC2=CC=CC=C2C=1NC1=CC=CC=C1 MTSNDBYBIZSILH-UHFFFAOYSA-N 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 150000003440 styrenes Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- YUYJJGBJTPXCEV-LVEZLNDCSA-N (e)-but-2-enedioic acid;n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 YUYJJGBJTPXCEV-LVEZLNDCSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WQRYDDUXWFSPQG-UHFFFAOYSA-N 1-(2-chloroethyl)imidazole Chemical compound ClCCN1C=CN=C1 WQRYDDUXWFSPQG-UHFFFAOYSA-N 0.000 description 1
- VFLQQZCRHPIGJU-UHFFFAOYSA-N 1-(2-chloroethyl)piperidine;hydron;chloride Chemical compound Cl.ClCCN1CCCCC1 VFLQQZCRHPIGJU-UHFFFAOYSA-N 0.000 description 1
- FSNGFFWICFYWQC-UHFFFAOYSA-N 1-(2-chloroethyl)pyrrolidine;hydron;chloride Chemical compound Cl.ClCCN1CCCC1 FSNGFFWICFYWQC-UHFFFAOYSA-N 0.000 description 1
- OBOBUDMMFXRNDO-UHFFFAOYSA-N 1-(3-chloropropyl)piperidine;hydron;chloride Chemical compound Cl.ClCCCN1CCCCC1 OBOBUDMMFXRNDO-UHFFFAOYSA-N 0.000 description 1
- UUPCYQIIQHSPKR-UHFFFAOYSA-N 1-(3-chloropropyl)pyrrolidine;hydrochloride Chemical compound Cl.ClCCCN1CCCC1 UUPCYQIIQHSPKR-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- COMSCFFBTPULJA-UHFFFAOYSA-N 1-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxy-3-morpholin-4-ylpropan-2-ol Chemical compound C=12C=C(OCC(O)CN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 COMSCFFBTPULJA-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- CEPCPXLLFXPZGW-UHFFFAOYSA-N 2,4-difluoroaniline Chemical compound NC1=CC=C(F)C=C1F CEPCPXLLFXPZGW-UHFFFAOYSA-N 0.000 description 1
- RAGSWDIQBBZLLL-UHFFFAOYSA-N 2-chloroethyl(diethyl)azanium;chloride Chemical compound Cl.CCN(CC)CCCl RAGSWDIQBBZLLL-UHFFFAOYSA-N 0.000 description 1
- LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 1
- BWYJJZBRYSADRP-UHFFFAOYSA-N 2-methoxyquinazoline Chemical compound C1=CC=CC2=NC(OC)=NC=C21 BWYJJZBRYSADRP-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- AXNUZKSSQHTNPZ-UHFFFAOYSA-N 3,4-difluoroaniline Chemical compound NC1=CC=C(F)C(F)=C1 AXNUZKSSQHTNPZ-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- FTZIQBGFCYJWKA-UHFFFAOYSA-N 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 FTZIQBGFCYJWKA-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- YSEMCVGMNUUNRK-UHFFFAOYSA-N 3-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Cl)=C1 YSEMCVGMNUUNRK-UHFFFAOYSA-N 0.000 description 1
- NBJHDLKSWUDGJG-UHFFFAOYSA-N 4-(2-chloroethyl)morpholin-4-ium;chloride Chemical compound Cl.ClCCN1CCOCC1 NBJHDLKSWUDGJG-UHFFFAOYSA-N 0.000 description 1
- PQECODMSWJOUAT-UHFFFAOYSA-N 4-(3-chloropropyl)morpholine;hydrochloride Chemical compound [Cl-].ClCCC[NH+]1CCOCC1 PQECODMSWJOUAT-UHFFFAOYSA-N 0.000 description 1
- WFOGDVXKFPKAIQ-UHFFFAOYSA-N 6-[2-[bis(2-methoxyethyl)amino]ethoxy]-n-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine Chemical compound N1=CN=C2C=C(OC)C(OCCN(CCOC)CCOC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 WFOGDVXKFPKAIQ-UHFFFAOYSA-N 0.000 description 1
- JXDDYWNTKTYLCD-UHFFFAOYSA-N 6-[3-(diethylamino)propoxy]-n-(3,4-difluorophenyl)-7-methoxyquinazolin-4-amine Chemical compound N1=CN=C2C=C(OC)C(OCCCN(CC)CC)=CC2=C1NC1=CC=C(F)C(F)=C1 JXDDYWNTKTYLCD-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 101100127890 Caenorhabditis elegans let-23 gene Proteins 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 101710137199 Class II receptor tyrosine kinase Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- LSPANGZZENHZNJ-UHFFFAOYSA-N PD-153035 Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Br)=C1 LSPANGZZENHZNJ-UHFFFAOYSA-N 0.000 description 1
- 108010055723 PDGF receptor tyrosine kinase Proteins 0.000 description 1
- 101150057744 PDGFA gene Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- ZRUSJEVFAQGVNB-UHFFFAOYSA-N S(=O)(=O)(O)OS(=O)(=O)O.ClC=1C=C(NC2=NC=NC3=CC(=C(C=C23)OCCCN2CCOCC2)OC)C=CC1F Chemical compound S(=O)(=O)(O)OS(=O)(=O)O.ClC=1C=C(NC2=NC=NC3=CC(=C(C=C23)OCCCN2CCOCC2)OC)C=CC1F ZRUSJEVFAQGVNB-UHFFFAOYSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 101100429091 Xiphophorus maculatus xmrk gene Proteins 0.000 description 1
- IFNQTATWQFILMW-UHFFFAOYSA-N [4-(2,4-difluoroanilino)-7-methoxyquinazolin-6-yl] acetate;hydrochloride Chemical compound Cl.C=12C=C(OC(C)=O)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C=C1F IFNQTATWQFILMW-UHFFFAOYSA-N 0.000 description 1
- XTDALRRLNKMRLD-UHFFFAOYSA-N [4-(3,4-difluoroanilino)-7-methoxyquinazolin-6-yl] acetate;hydrochloride Chemical compound Cl.C=12C=C(OC(C)=O)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(F)=C1 XTDALRRLNKMRLD-UHFFFAOYSA-N 0.000 description 1
- RBFWFFFXYPQXHG-UHFFFAOYSA-N [4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl] acetate;hydrochloride Chemical compound Cl.C=12C=C(OC(C)=O)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 RBFWFFFXYPQXHG-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000001109 blastomere Anatomy 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 1
- SIHZWGODIRRSRA-ONEGZZNKSA-N erbstatin Chemical compound OC1=CC=C(O)C(\C=C\NC=O)=C1 SIHZWGODIRRSRA-ONEGZZNKSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000012444 intercalating antibiotic Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- JUBFKEWLPTXFBA-UHFFFAOYSA-N n-(2,4-difluorophenyl)-6-[3-(dimethylamino)propoxy]-7-methoxyquinazolin-4-amine Chemical compound C=12C=C(OCCCN(C)C)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C=C1F JUBFKEWLPTXFBA-UHFFFAOYSA-N 0.000 description 1
- QRIMOJCHBRNQII-UHFFFAOYSA-N n-(2,4-difluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C=C1F QRIMOJCHBRNQII-UHFFFAOYSA-N 0.000 description 1
- SCLNZCBZYOKZJY-UHFFFAOYSA-N n-(3,4-difluorophenyl)-6-[3-(dimethylamino)propoxy]-7-methoxyquinazolin-4-amine Chemical compound C=12C=C(OCCCN(C)C)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(F)=C1 SCLNZCBZYOKZJY-UHFFFAOYSA-N 0.000 description 1
- MEDBJFRRWZWOFV-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-6-(3-imidazol-1-ylpropoxy)-7-methoxyquinazolin-4-amine Chemical compound C=12C=C(OCCCN3C=NC=C3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 MEDBJFRRWZWOFV-UHFFFAOYSA-N 0.000 description 1
- OOSIXUJCRGYBQJ-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-6-[2-(diethylamino)ethoxy]-7-methoxyquinazolin-4-amine Chemical compound N1=CN=C2C=C(OC)C(OCCN(CC)CC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 OOSIXUJCRGYBQJ-UHFFFAOYSA-N 0.000 description 1
- CBVZLUIKUXDQLU-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-6-[2-(dimethylamino)ethoxy]-7-methoxyquinazolin-4-amine Chemical compound C=12C=C(OCCN(C)C)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 CBVZLUIKUXDQLU-UHFFFAOYSA-N 0.000 description 1
- QXZNYTGAAOAYAM-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(2-piperidin-1-ylethoxy)quinazolin-4-amine Chemical compound C=12C=C(OCCN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 QXZNYTGAAOAYAM-UHFFFAOYSA-N 0.000 description 1
- OOSLLKQMGOLSHO-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 OOSLLKQMGOLSHO-UHFFFAOYSA-N 0.000 description 1
- YYVGAKQEJHTNFP-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 YYVGAKQEJHTNFP-UHFFFAOYSA-N 0.000 description 1
- UEWRHTSERXIBRC-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-methoxy-6-[2-(4-methylpiperazin-1-yl)ethoxy]quinazolin-4-amine Chemical compound C=12C=C(OCCN3CCN(C)CC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 UEWRHTSERXIBRC-UHFFFAOYSA-N 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9508538.7A GB9508538D0 (en) | 1995-04-27 | 1995-04-27 | Quinazoline derivatives |
| PCT/GB1996/000961 WO1996033980A1 (en) | 1995-04-27 | 1996-04-23 | Quinazoline derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO974940L NO974940L (no) | 1997-10-24 |
| NO974940D0 NO974940D0 (no) | 1997-10-24 |
| NO309472B1 true NO309472B1 (no) | 2001-02-05 |
Family
ID=10773597
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO974940A NO309472B1 (no) | 1995-04-27 | 1997-10-24 | Kinazolin-derivater, anvendelse og fremstilling derav, samt farmasöytisk preparat |
| NO2009028C NO2009028I1 (no) | 1995-04-27 | 2009-12-16 | Kinazolin-derivater, anvendelse og fremstilling derav, samt farmasøytisk preparat |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO2009028C NO2009028I1 (no) | 1995-04-27 | 2009-12-16 | Kinazolin-derivater, anvendelse og fremstilling derav, samt farmasøytisk preparat |
Country Status (38)
Families Citing this family (743)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6811779B2 (en) | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
| TW321649B (enExample) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| GB9508535D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
| GB9508537D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| AU5343096A (en) * | 1995-04-27 | 1996-11-18 | Zeneca Limited | Quinazoline derivatives |
| GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DE69720965T2 (de) | 1996-02-13 | 2004-02-05 | Astrazeneca Ab | Chinazolinderivate und deren verwendung als vegf hemmer |
| GB9603097D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| PT885198E (pt) | 1996-03-05 | 2002-06-28 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina |
| US6344459B1 (en) | 1996-04-12 | 2002-02-05 | Warner-Lambert Company | Irreversible inhibitors of tyrosine kinases |
| GB9607729D0 (en) * | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| CA2299471C (en) * | 1997-08-15 | 2007-12-18 | Cephalon Inc. | Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer |
| ATE368665T1 (de) | 1997-08-22 | 2007-08-15 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
| US20030224001A1 (en) * | 1998-03-19 | 2003-12-04 | Goldstein Neil I. | Antibody and antibody fragments for inhibiting the growth of tumors |
| US6864227B1 (en) * | 1998-04-13 | 2005-03-08 | California Institute Of Technology | Artery-and vein-specific proteins and uses therefor |
| US6887674B1 (en) * | 1998-04-13 | 2005-05-03 | California Institute Of Technology | Artery- and vein-specific proteins and uses therefor |
| ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
| US7354894B2 (en) * | 1998-08-18 | 2008-04-08 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
| DE69939022D1 (de) | 1998-08-18 | 2008-08-14 | Univ California | Epidermale wachstumsfaktor rezeptor antagonisten zur behandlung stark vermehrter schleimsekretion in der lunge |
| ATE292121T1 (de) | 1998-08-21 | 2005-04-15 | Parker Hughes Inst | Chinazolinderivate |
| US6288082B1 (en) | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| SI2253620T1 (sl) | 1998-09-29 | 2014-06-30 | Wyeth Holdings Llc | Substituirani 3-cianokinolini kot inhibitorji protein tirozin-kinaz |
| US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| PT1135153E (pt) * | 1998-11-20 | 2005-09-30 | Genentech Inc | Utilizacoes para antagonistas e agonistas de receptores eph para tratar desordens vasculares |
| ID29800A (id) | 1999-02-27 | 2001-10-11 | Boehringer Ingelheim Pharma | Turunan-turunan 4-amino-kinazolin dan kinolin yang mempunyai efek inhibitor pada transduksi signal yang dimediasi oleh tirosin kinase |
| DE19911509A1 (de) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| WO2000069459A1 (en) * | 1999-05-14 | 2000-11-23 | Imclone Systems Incorporated | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
| PT1731511E (pt) | 1999-06-21 | 2015-11-13 | Boehringer Ingelheim Pharma | Heterociclos bicíclicos, medicamentos contendo estes compostos, a sua utilização e processos para a sua preparação |
| US6432979B1 (en) | 1999-08-12 | 2002-08-13 | American Cyanamid Company | Method of treating or inhibiting colonic polyps and colorectal cancer |
| GB9925958D0 (en) * | 1999-11-02 | 1999-12-29 | Bundred Nigel J | Therapeutic use |
| UA72946C2 (uk) * | 1999-11-05 | 2005-05-16 | Астразенека Аб | Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf) |
| US20020002169A1 (en) | 1999-12-08 | 2002-01-03 | Griffin John H. | Protein kinase inhibitors |
| GB0002952D0 (en) * | 2000-02-09 | 2000-03-29 | Pharma Mar Sa | Process for producing kahalalide F compounds |
| GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0008368D0 (en) * | 2000-04-06 | 2000-05-24 | Astrazeneca Ab | Combination product |
| DE60121931T2 (de) | 2000-04-07 | 2007-03-01 | Astrazeneca Ab | Chinazolinverbindungen |
| EP1170011A1 (en) * | 2000-07-06 | 2002-01-09 | Boehringer Ingelheim International GmbH | Novel use of inhibitors of the epidermal growth factor receptor |
| AU9500201A (en) * | 2000-08-09 | 2002-02-18 | Imclone Systems Inc | Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
| US6740651B2 (en) | 2000-08-26 | 2004-05-25 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
| US6403580B1 (en) | 2000-08-26 | 2002-06-11 | Boehringer Ingelheim Pharma Kg | Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| DE10042058A1 (de) * | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE10042059A1 (de) * | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US6656946B2 (en) | 2000-08-26 | 2003-12-02 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
| US6617329B2 (en) | 2000-08-26 | 2003-09-09 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines and their use as medicaments |
| EP1326860A1 (en) * | 2000-10-13 | 2003-07-16 | AstraZeneca AB | Quinazoline derivatives |
| EP1506962B1 (en) | 2000-10-20 | 2008-07-02 | Eisai R&D Management Co., Ltd. | Nitrogen-containing aromatic heterocycles |
| DE10206505A1 (de) * | 2002-02-16 | 2003-08-28 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und EGFR-Kinase-Hemmern |
| US7776315B2 (en) | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
| DE60144284D1 (de) | 2000-11-01 | 2011-05-05 | Millennium Pharm Inc | Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung |
| US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| EP2762140B1 (en) | 2001-02-19 | 2017-03-22 | Novartis AG | Treatment of solid brain tumours with a rapamycin derivative |
| US20080008704A1 (en) * | 2001-03-16 | 2008-01-10 | Mark Rubin | Methods of treating colorectal cancer with anti-epidermal growth factor antibodies |
| HUP0400038A3 (en) | 2001-05-16 | 2007-05-29 | Novartis Ag | Combination comprising n-{5-[4-{-methyl-piperazino-methyl)-benzoylamino]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent |
| EP1408980A4 (en) | 2001-06-21 | 2004-10-20 | Ariad Pharma Inc | NEW QUINAZOLINES AND THEIR USE |
| US7402585B2 (en) * | 2001-12-24 | 2008-07-22 | Astrazeneca Ab | Substituted quinazoline derivatives as inhibitors of aurora kinases |
| DE10204462A1 (de) * | 2002-02-05 | 2003-08-07 | Boehringer Ingelheim Pharma | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
| EP1481971B1 (en) | 2002-02-06 | 2011-11-16 | Ube Industries, Ltd. | Process for producing 4-aminoquinazoline compound |
| GB0204392D0 (en) * | 2002-02-26 | 2002-04-10 | Astrazeneca Ab | Pharmaceutical compound |
| IL163689A0 (en) * | 2002-02-26 | 2005-12-18 | Astrazeneca Ab | Novel crystalline forms of the anti-cancer compound zd1839 |
| DK1480679T3 (da) * | 2002-02-26 | 2007-09-03 | Astrazeneca Ab | Farmaceutisk formulering af iressa, der omfatter et vandoplöseligt cellulosederivat |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| RU2345989C2 (ru) * | 2002-03-28 | 2009-02-10 | Астразенека Аб | Производные 4-анилино-хиназолина, способ их получения (варианты), фармацевтическая композиция, способ ингибирования пролиферативного действия и способ лечения рака у теплокровного животного |
| TWI324597B (en) * | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| AU2003216558B2 (en) * | 2002-04-16 | 2008-05-29 | Astrazeneca Ab | Combination therapy for the treatment of cancer |
| DE10221018A1 (de) * | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
| BR0311173A (pt) | 2002-05-16 | 2005-03-15 | Novartis Ag | Uso de agentes de ligação do receptor de edg em câncer |
| US20040048887A1 (en) * | 2002-07-09 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors |
| DK2263691T3 (da) | 2002-07-15 | 2012-10-22 | Hoffmann La Roche | Behandling af cancer med det rekombinante humaniserede monoklonale anti-ErbB2-antistof 2C4 (rhuMAb-2C4) |
| WO2004006846A2 (en) * | 2002-07-15 | 2004-01-22 | Exelixis, Inc. | Receptor-type kinase modulators and methods of use |
| GB0221245D0 (en) * | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Chemical process |
| CN101987871A (zh) | 2002-09-27 | 2011-03-23 | 赞科股份有限公司 | 优化的Fc变体及其产生方法 |
| GB0223854D0 (en) * | 2002-10-12 | 2002-11-20 | Astrazeneca Ab | Therapeutic treatment |
| GB0304367D0 (en) * | 2003-02-26 | 2003-04-02 | Pharma Mar Sau | Methods for treating psoriasis |
| SI1562955T1 (sl) * | 2002-11-04 | 2008-06-30 | Astrazeneca Ab | Derivati kinazolina kot inhibitorji Src-triozin kinaze |
| NZ540092A (en) | 2002-11-20 | 2007-06-29 | Array Biopharma Inc | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
| JPWO2004060400A1 (ja) * | 2003-01-06 | 2006-05-11 | 那波 宏之 | 上皮成長因子受容体を分子標的とする抗精神病薬 |
| GEP20084540B (en) | 2003-01-14 | 2008-11-25 | Arena Pharm Inc | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| GB0302882D0 (en) * | 2003-02-07 | 2003-03-12 | Univ Cardiff | Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss |
| US7223749B2 (en) | 2003-02-20 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| EP1604665B1 (en) | 2003-03-10 | 2011-05-11 | Eisai R&D Management Co., Ltd. | C-kit kinase inhibitor |
| EP1605961A4 (en) * | 2003-03-12 | 2009-11-11 | Vasgene Therapeutics Inc | POLYPEPTIDE COMPOUNDS FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH |
| US7381410B2 (en) * | 2003-03-12 | 2008-06-03 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| EP1622941A2 (en) * | 2003-03-20 | 2006-02-08 | ImClone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
| GB0309850D0 (en) | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
| US7417065B2 (en) | 2003-05-19 | 2008-08-26 | Irm Llc | Immunosuppressant compounds and compositions |
| MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| JO2785B1 (en) | 2003-05-27 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinazoline derivatives |
| WO2005049829A1 (en) | 2003-05-30 | 2005-06-02 | Astrazeneca Uk Limited | Process |
| DE10326186A1 (de) | 2003-06-06 | 2004-12-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| CN1972712A (zh) | 2003-06-09 | 2007-05-30 | 塞缪尔·瓦克萨尔 | 用胞外拮抗物和胞内拮抗物抑制受体酪氨酸激酶的方法 |
| AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| EP1648998B1 (en) | 2003-07-18 | 2014-10-01 | Amgen Inc. | Specific binding agents to hepatocyte growth factor |
| KR20060054388A (ko) * | 2003-07-29 | 2006-05-22 | 아스트라제네카 아베 | 티로신 키나아제 억제제로서의 피페리딜-퀴나졸린 유도체 |
| GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
| GB0317663D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Pharmaceutical composition |
| KR100953246B1 (ko) * | 2003-08-14 | 2010-04-16 | 어레이 바이오파마 인크. | 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체 |
| GB0320793D0 (en) * | 2003-09-05 | 2003-10-08 | Astrazeneca Ab | Chemical process |
| GB0321066D0 (en) * | 2003-09-09 | 2003-10-08 | Pharma Mar Sau | New antitumoral compounds |
| MXPA06003161A (es) * | 2003-09-16 | 2006-06-05 | Astrazeneca Ab | Derivados de quinazolina. |
| AU2004272348B2 (en) * | 2003-09-16 | 2008-09-04 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
| DE602004004811T2 (de) * | 2003-09-19 | 2007-11-22 | Astrazeneca Ab | Chinazolinderivate |
| DK1667992T3 (da) * | 2003-09-19 | 2007-04-30 | Astrazeneca Ab | Quinazolinderivater |
| GB0322409D0 (en) | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
| WO2005030757A1 (en) * | 2003-09-25 | 2005-04-07 | Astrazeneca Ab | Quinazoline derivatives |
| PL2392565T3 (pl) * | 2003-09-26 | 2014-08-29 | Exelixis Inc | Modulatory c-Met i sposoby stosowania |
| US7456189B2 (en) | 2003-09-30 | 2008-11-25 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
| DE10349113A1 (de) | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
| PL2489364T3 (pl) | 2003-11-06 | 2015-06-30 | Seattle Genetics Inc | Związki monometylowaliny zdolne do sprzęgania do przeciwciał |
| JP4303726B2 (ja) | 2003-11-11 | 2009-07-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア誘導体およびその製造方法 |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| DE602004012891T2 (de) | 2003-12-18 | 2009-04-09 | Janssen Pharmaceutica N.V. | Pyrido- und pyrimidopyrimidinderivate als anti-proliferative mittel |
| AU2003290345A1 (en) * | 2003-12-24 | 2005-07-14 | Astrazeneca Ab | Pharmaceutical dissolution testing using a non-ionic surfactant |
| WO2005070909A1 (en) * | 2004-01-22 | 2005-08-04 | Natco Pharma Limited | An improved process for the preparation of gefitinib |
| WO2005075439A1 (en) | 2004-02-03 | 2005-08-18 | Astrazeneca Ab | Quinazoline derivatives |
| KR20120123619A (ko) | 2004-03-12 | 2012-11-08 | 바스진 테라퓨틱스, 인크. | 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물 |
| CN101072797B (zh) * | 2004-03-12 | 2012-05-09 | 瓦斯基因治疗公司 | 结合ephb4、抑制血管发生和肿瘤生长的抗体 |
| JP4734319B2 (ja) * | 2004-03-19 | 2011-07-27 | イムクローン・リミテッド・ライアビリティ・カンパニー | ヒト抗上皮成長因子受容体抗体 |
| CN104480200B (zh) | 2004-03-31 | 2017-12-29 | 综合医院公司 | 测定癌症对表皮生长因子受体靶向性治疗反应性的方法 |
| WO2005097134A2 (en) * | 2004-03-31 | 2005-10-20 | The Scripps Research Institute | Quinazoline based protein kinase inhibitors |
| PL2253614T3 (pl) | 2004-04-07 | 2013-03-29 | Novartis Ag | Inhibitory IAP |
| RS52119B (sr) * | 2004-05-06 | 2012-08-31 | Warner-Lambert Company Llc | 4-fenilamino-hinazolin-6-il-amidi |
| WO2005107747A2 (en) * | 2004-05-06 | 2005-11-17 | Bioresponse, Llc | Diindolymethane formulations for the treatment of leiomyomas |
| CN114053429A (zh) | 2004-06-01 | 2022-02-18 | 健泰科生物技术公司 | 抗体-药物偶联物和方法 |
| EP2277595A3 (en) | 2004-06-24 | 2011-09-28 | Novartis Vaccines and Diagnostics, Inc. | Compounds for immunopotentiation |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| EP2471813B1 (en) | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
| ATE428421T1 (de) | 2004-09-17 | 2009-05-15 | Eisai R&D Man Co Ltd | Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften |
| EP1799713B1 (en) | 2004-09-23 | 2014-11-05 | VasGene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| BRPI0516284A (pt) | 2004-09-23 | 2008-09-02 | Genentech Inc | anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| CA2587642C (en) | 2004-11-30 | 2013-04-09 | Amgen Inc. | Substituted heterocycles and methods of use |
| NI200700147A (es) | 2004-12-08 | 2019-05-10 | Janssen Pharmaceutica Nv | Derivados de quinazolina inhibidores de cinasas dirigidos a multip |
| JO3088B1 (ar) * | 2004-12-08 | 2017-03-15 | Janssen Pharmaceutica Nv | مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف |
| DE602005026865D1 (de) | 2004-12-14 | 2011-04-21 | Astrazeneca Ab | Pyrazolopyrimidinverbindungen als antitumormittel |
| EP1838303B1 (en) | 2004-12-30 | 2011-02-09 | Bioresponse LLC | Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associates conditions |
| DOP2006000010A (es) | 2005-01-10 | 2006-07-31 | Arena Pharm Inc | Procedimiento para preparar eteres aromáticos |
| UA94899C2 (ru) | 2005-01-21 | 2011-06-25 | Дженентек, Инк. | Фиксированное дозирование антител к her |
| MX2007008810A (es) | 2005-01-21 | 2007-11-21 | Astex Therapeutics Ltd | Compuestos farmaceuticos. |
| GB0501999D0 (en) * | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| AU2006210572B2 (en) | 2005-02-03 | 2011-08-04 | The General Hospital Corporation | Method for treating gefitinib resistant cancer |
| US20090155247A1 (en) * | 2005-02-18 | 2009-06-18 | Ashkenazi Avi J | Methods of Using Death Receptor Agonists and EGFR Inhibitors |
| US20060188498A1 (en) * | 2005-02-18 | 2006-08-24 | Genentech, Inc. | Methods of using death receptor agonists and EGFR inhibitors |
| CN101163503B (zh) | 2005-02-23 | 2013-05-08 | 健泰科生物技术公司 | 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活 |
| WO2006090413A1 (en) * | 2005-02-23 | 2006-08-31 | Natco Pharma Limited | Novel crystalline form of gefitinib and a process for its preparation |
| US8735410B2 (en) | 2005-02-26 | 2014-05-27 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
| PL1859793T3 (pl) * | 2005-02-28 | 2011-09-30 | Eisai R&D Man Co Ltd | Nowe połączone zastosowanie związku sulfonamidowego w leczeniu choroby nowotworowej |
| US20060216288A1 (en) * | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
| EP1871345B1 (en) * | 2005-04-12 | 2012-08-01 | Elan Pharma International Limited | Nanoparticulate erlotinib formulations |
| NZ562223A (en) | 2005-04-19 | 2010-01-29 | Smithkline Beecham Cork Ltd | Pharmaceutical composition comprising lapatinib or N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]4-quinazolinamine |
| WO2006119674A1 (en) * | 2005-05-12 | 2006-11-16 | Wenlin Huang | The preparation process of quinazoline derivatives and application for the manufacture for the treatment of tumor disease |
| CN101175732B (zh) * | 2005-05-12 | 2010-06-16 | 黄文林 | 一种喹唑啉衍生物的制备方法及用作制备治疗肿瘤疾病药物的应用 |
| WO2006119676A1 (en) * | 2005-05-12 | 2006-11-16 | Wenlin Huang | The preparation process of quinazoline derivatives and application for the manufacture for the treatment of tumor disease |
| BRPI0610360A2 (pt) | 2005-05-13 | 2010-06-15 | Novartis Ag | métodos para tratar de cáncer resistente a fármaco |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| SI2100618T1 (sl) | 2005-06-17 | 2014-03-31 | Imclone Llc | Antagonisti receptorja za zdravljenje metastaznega kostnega raka |
| AU2006268227A1 (en) | 2005-07-08 | 2007-01-18 | Xencor, Inc | Optimized anti-Ep-CAM antibodies |
| SG164368A1 (en) * | 2005-07-18 | 2010-09-29 | Bipar Sciences Inc | Treatment of cancer |
| JP5066446B2 (ja) * | 2005-08-01 | 2012-11-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を予測する方法 |
| EP2281901B1 (en) | 2005-08-02 | 2013-11-27 | Eisai R&D Management Co., Ltd. | Anti-tumour pharmaceutical composition with angiogenesis inhibitors |
| WO2007025044A2 (en) | 2005-08-24 | 2007-03-01 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
| CN1300118C (zh) * | 2005-08-25 | 2007-02-14 | 江苏吴中苏药医药开发有限责任公司 | 4－(3－氯－4－氟苯基胺基)－7－甲氧基－6－(3－吗啉丙氧基)喹唑啉的制备方法 |
| CN101277720A (zh) * | 2005-09-01 | 2008-10-01 | 卫材R&D管理有限公司 | 崩解性被改善的药物组合物的制备方法 |
| EP1928861B1 (en) | 2005-09-20 | 2010-11-17 | AstraZeneca AB | 4- (ih-indazol-5-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer |
| CA2623387A1 (en) * | 2005-09-23 | 2007-04-05 | Vasgene Therapeutics, Inc. | Use of ephrinb2 directed agents for the treatment or prevention of viral infections |
| EP3488866A1 (en) | 2005-11-04 | 2019-05-29 | Wyeth LLC | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
| CA2627598C (en) | 2005-11-07 | 2013-06-25 | Eisai R & D Management Co., Ltd. | Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
| EP1948179A1 (en) | 2005-11-11 | 2008-07-30 | Boehringer Ingelheim International GmbH | Quinazoline derivatives for the treatment of cancer diseases |
| JP2009516671A (ja) | 2005-11-21 | 2009-04-23 | ノバルティス アクチエンゲゼルシャフト | ｍＴＯＲ阻害剤を使用する神経内分泌腫瘍処置 |
| WO2007061130A1 (ja) * | 2005-11-22 | 2007-05-31 | Eisai R & D Management Co., Ltd. | 多発性骨髄腫に対する抗腫瘍剤 |
| US7977346B2 (en) * | 2006-01-17 | 2011-07-12 | Guoqing Paul Chen | Spiro compounds and methods of use |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| CN101003514A (zh) | 2006-01-20 | 2007-07-25 | 上海艾力斯医药科技有限公司 | 喹唑啉衍生物、其制备方法及用途 |
| AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| PE20070978A1 (es) * | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
| GB0605120D0 (en) | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
| US20070231298A1 (en) * | 2006-03-31 | 2007-10-04 | Cell Genesys, Inc. | Cytokine-expressing cancer immunotherapy combinations |
| BRPI0709750A2 (pt) | 2006-04-05 | 2011-07-26 | Novartis Ag | combinaÇÕes de agentes terapÊuticos para tratamento de cÂncer |
| CA2644143C (en) | 2006-04-05 | 2013-10-01 | Novartis Ag | Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer |
| AR060358A1 (es) * | 2006-04-06 | 2008-06-11 | Novartis Vaccines & Diagnostic | Quinazolinas para la inhibicion de pdk 1 |
| CA2648809A1 (en) | 2006-04-19 | 2007-11-01 | Novartis Ag | Indazole compounds and methods for inhibition of cdc7 |
| PE20080695A1 (es) | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
| AU2007247112B2 (en) | 2006-05-09 | 2010-08-26 | Novartis Ag | Combination comprising an iron chelator and an anti-neoplastic agent and use thereof |
| WO2007136103A1 (ja) | 2006-05-18 | 2007-11-29 | Eisai R & D Management Co., Ltd. | 甲状腺癌に対する抗腫瘍剤 |
| US20070292883A1 (en) * | 2006-06-12 | 2007-12-20 | Ossovskaya Valeria S | Method of treating diseases with PARP inhibitors |
| US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| EP2044939A1 (en) * | 2006-06-29 | 2009-04-08 | Eisai R&D Management Co., Ltd. | Therapeutic agent for liver fibrosis |
| MX2009000456A (es) | 2006-07-13 | 2009-01-27 | Janssen Pharmaceutica Nv | Derivados de quinazolina mtki. |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| DK2059536T3 (da) | 2006-08-14 | 2014-04-14 | Xencor Inc | Optimerede antistoffer, der er rettet mod cd19 |
| KR101472600B1 (ko) | 2006-08-28 | 2014-12-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암에 대한 항종양제 |
| JP2008081492A (ja) | 2006-08-31 | 2008-04-10 | Banyu Pharmaceut Co Ltd | オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体 |
| WO2008030891A2 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof |
| AU2007292387A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
| US7977347B2 (en) * | 2006-09-11 | 2011-07-12 | Curis, Inc. | Quinazoline based EGFR inhibitors |
| EP2845912A1 (en) | 2006-09-12 | 2015-03-11 | Genentech, Inc. | Methods and compositions for the diagnosis and treatment of lung cancer using KIT gene as genetic marker |
| MX2009002710A (es) | 2006-09-18 | 2009-03-25 | Boehringer Ingelheim Int | Metodos para tratar canceres que portan mutaciones de egfr. |
| WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
| WO2008044041A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| JP5528807B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| WO2008046242A1 (fr) * | 2006-10-16 | 2008-04-24 | Institute Of Mataria Medica, Chinese Academy Of Medical Sciences | Nouveaux dérivés quinazolines, leurs procédés de préparation et leurs utilisations |
| KR20090091119A (ko) * | 2006-10-27 | 2009-08-26 | 얀센 파마슈티카 엔.브이. | 뇌암을 치료하거나 예방하기 위한 ｍｔ 키나아제 저해제의 용도 |
| BRPI0717753B1 (pt) | 2006-10-27 | 2022-04-12 | Bioresponse, Llc | Uso de uma composição compreendendo 50-250 mg de um ou mais indóis relacionados com dim e um ou mais agentes anti-protozoários, e, composição |
| US7851623B2 (en) | 2006-11-02 | 2010-12-14 | Astrazeneca Ab | Chemical process |
| EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| EP2125841A1 (en) * | 2006-12-13 | 2009-12-02 | Gilead Sciences, Inc. | Monophosphates as mutual prodrugs of anti-inflammatory signal transduction modulators (aistm's) and beta-agonists for the treatment of pulmonary inflammation and bronchoconstriction |
| US7687522B2 (en) | 2006-12-20 | 2010-03-30 | Amgen Inc. | Substituted pyridines and pyrimidines and their use in treatment of cancer |
| US7977336B2 (en) | 2006-12-28 | 2011-07-12 | Banyu Pharmaceutical Co. Ltd | Aminopyrimidine derivatives as PLK1 inhibitors |
| ES2449482T3 (es) | 2007-01-09 | 2014-03-19 | Amgen Inc. | Derivados de bis-aril-amida útiles para el tratamiento de cáncer |
| KR101445892B1 (ko) | 2007-01-29 | 2014-09-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암 치료용 조성물 |
| BRPI0807234A2 (pt) | 2007-02-06 | 2014-06-03 | Boehringer Ingelheim Int | Heterociclos bicíclicos, composições farmacêuticas que contêm estes compostos, o uso dos mesmos e processos para a preparação dos mesmos |
| RU2009134223A (ru) | 2007-02-15 | 2011-03-20 | Новартис АГ (CH) | Комбинация lbh589 с другими терапевтическими средствами, предназначенная для лечения рака |
| WO2008103277A2 (en) | 2007-02-16 | 2008-08-28 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
| CN101680897B (zh) | 2007-03-02 | 2013-11-13 | 健泰科生物技术公司 | 基于低her3表达预测对her二聚化抑制剂的响应 |
| WO2008121346A1 (en) * | 2007-03-30 | 2008-10-09 | Massachusetts Institute Of Technology | Methods for identifying compounds that modulate neurotrophic factor signaling |
| KR20100017101A (ko) | 2007-04-16 | 2010-02-16 | 시플라 리미티드 | 게피티닙의 제조방법 |
| AU2008260498B2 (en) | 2007-05-30 | 2012-11-29 | Xencor, Inc. | Methods and compositions for inhibiting CD32b expressing cells |
| ES2417148T3 (es) | 2007-06-08 | 2013-08-06 | Genentech, Inc. | Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2 |
| DK2170827T3 (da) * | 2007-06-21 | 2013-11-18 | Janssen Pharmaceutica Nv | Indolin-2-oner og aza-indolin-2-oner |
| AU2008281849B2 (en) | 2007-07-27 | 2013-11-28 | Janssen Pharmaceutica Nv | Pyrrolopyrimidines |
| CA2696164C (en) * | 2007-08-13 | 2018-06-12 | Vasgene Therapeutics, Inc. | Cancer treatment using humanized antibodies that bind to ephb4 |
| PT2188313T (pt) | 2007-08-21 | 2017-12-12 | Amgen Inc | Proteínas de ligação ao antigénio c-fms humano |
| JP5474792B2 (ja) * | 2007-09-10 | 2014-04-16 | キュリス，インコーポレイテッド | 亜鉛結合部分を含むキナゾリンベースｅｇｆｒインヒビターの酒石酸塩またはその複合体 |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| JP2011500684A (ja) * | 2007-10-19 | 2011-01-06 | バイパー サイエンシズ，インコーポレイティド | ベンゾピロン系ｐａｒｐ阻害剤を用いる癌の処置方法および組成物 |
| EP2207561A2 (en) * | 2007-10-19 | 2010-07-21 | Pharma Mar, S.A. | Improved antitumoral treatments |
| AU2008315048A1 (en) | 2007-10-23 | 2009-04-30 | Msd K.K. | Pyridone-substituted-dihydropyrazolopyrimidinone derivative |
| KR20100087185A (ko) * | 2007-10-29 | 2010-08-03 | 낫코 파마 리미티드 | 항암제로서의 신규한 4-(테트라졸-5-일)-퀴나졸린 유도체 |
| KR101513326B1 (ko) | 2007-11-09 | 2015-04-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 항종양성 백금 착물의 병용 |
| JP2011503111A (ja) * | 2007-11-12 | 2011-01-27 | バイパー サイエンシズ，インコーポレイティド | Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療 |
| US20090123419A1 (en) * | 2007-11-12 | 2009-05-14 | Bipar Sciences | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| WO2009067543A2 (en) * | 2007-11-19 | 2009-05-28 | The Regents Of The University Of Colorado | Treatment of histone deacetylase mediated disorders |
| UY31478A1 (es) | 2007-11-21 | 2009-07-17 | Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo | |
| US20090149397A1 (en) * | 2007-12-07 | 2009-06-11 | Bipar Sciences | Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors |
| UY31545A1 (es) | 2007-12-20 | 2009-08-03 | Nuevos derivados de 2-carboxamida cianoaminourea, sus sales y profarmacos farmacéuticamente aceptables, procesos de preparacion y aplicaciones | |
| EA018514B1 (ru) | 2008-01-18 | 2013-08-30 | Натко Фарма Лимитед | 6,7-диалкокси хиназолиновые производные, эффективные для лечения нарушений, связанных с раком |
| WO2009094216A1 (en) * | 2008-01-22 | 2009-07-30 | Concert Pharmaceuticals Inc. | Derivatives of gefitinib |
| CN102036962B (zh) * | 2008-01-29 | 2013-08-07 | 卫材R&D管理有限公司 | 血管生成抑制剂和紫杉烷的组合使用 |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| AU2009209541A1 (en) * | 2008-01-30 | 2009-08-06 | Pharma Mar, S.A. | Improved antitumoral treatments |
| PT2245026E (pt) | 2008-02-07 | 2012-10-15 | Boehringer Ingelheim Int | Heterociclos espirocíclicos, produtos farmacêuticos contendo estes compostos, sua utilização e processo para a sua preparação |
| WO2009109605A1 (en) * | 2008-03-05 | 2009-09-11 | Novartis Ag | Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members |
| CN101965192A (zh) * | 2008-03-07 | 2011-02-02 | 法马马有限公司 | 改善的抗肿瘤治疗 |
| EA020114B1 (ru) | 2008-03-24 | 2014-08-29 | Новартис Аг | Производные арилсульфонамида в качестве ингибиторов матриксной металлопротеазы |
| CN101544609A (zh) | 2008-03-25 | 2009-09-30 | 上海艾力斯医药科技有限公司 | 4-苯胺喹唑啉衍生物的结晶形式 |
| JP5330498B2 (ja) | 2008-03-26 | 2013-10-30 | ノバルティス アーゲー | 脱アセチル化酵素ｂのヒドロキサメートを基にした阻害剤 |
| US8088782B2 (en) | 2008-05-13 | 2012-01-03 | Astrazeneca Ab | Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A |
| WO2009140409A1 (en) | 2008-05-14 | 2009-11-19 | Genomic Health Inc. | Predictors of patient response to treatment with egf receptor inhibitors |
| CN101584696A (zh) | 2008-05-21 | 2009-11-25 | 上海艾力斯医药科技有限公司 | 包含喹唑啉衍生物的组合物及制备方法、用途 |
| KR20110010787A (ko) | 2008-06-17 | 2011-02-07 | 와이어쓰 엘엘씨 | Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물 |
| DE102008031040A1 (de) | 2008-06-30 | 2009-12-31 | Alexander Priv.-Doz. Dr. Dömling | Iressa zur Anwendung in der Organtransplantation |
| CN113209121A (zh) | 2008-08-04 | 2021-08-06 | 惠氏有限责任公司 | 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合 |
| CA2733153C (en) | 2008-08-08 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
| CN101367793B (zh) * | 2008-09-26 | 2013-09-11 | 中国科学院广州生物医药与健康研究院 | 一种具有抗肿瘤活性的氨基喹唑啉衍生物及其盐类 |
| EP2344161B1 (en) | 2008-10-16 | 2018-12-19 | Celator Pharmaceuticals, Inc. | Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab |
| EP2349235A1 (en) | 2008-11-07 | 2011-08-03 | Triact Therapeutics, Inc. | Use of catecholic butane derivatives in cancer therapy |
| CA2745265A1 (en) * | 2008-12-01 | 2010-06-10 | James Turkson | Drug composition cytotoxic for pancreatic cancer cells |
| CN104803902A (zh) | 2008-12-18 | 2015-07-29 | 诺华股份有限公司 | 1-(4-{1-[(e)-4-环己基-3-三氟甲基-苄氧基亚氨基]-乙基}-2-乙基-苄基)-氮杂环丁烷-3-甲酸的半富马酸盐 |
| EP2379499B1 (en) | 2008-12-18 | 2014-04-09 | Novartis AG | Hydrochloride salt of 1-(4-(1-((E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl)-2-ethyl-benzyl)-azetidine-3-carboxylic acid |
| EP2379498B1 (en) | 2008-12-18 | 2015-01-21 | Novartis AG | Polymorphic form of 1-(4-{1-[(e)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl) -azetidine-3-carboxylic acid |
| EA038195B1 (ru) | 2009-01-16 | 2021-07-22 | Экселиксис, Инк. | Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее применение для лечения рака почек и печени |
| WO2010083617A1 (en) | 2009-01-21 | 2010-07-29 | Oncalis Ag | Pyrazolopyrimidines as protein kinase inhibitors |
| HRP20121006T1 (hr) | 2009-01-29 | 2013-01-31 | Novartis Ag | Supstituirani benzimidazoli za lijeäśenje astrocitoma |
| US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| AU2010218781A1 (en) | 2009-02-25 | 2011-07-28 | Msd K.K. | Pyrimidopyrimidoindazole derivative |
| JP2012519170A (ja) | 2009-02-26 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法 |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099364A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| EP2401614A1 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| US8481503B2 (en) | 2009-03-06 | 2013-07-09 | Merck Sharp & Dohme Corp. | Combination cancer therapy with an AKT inhibitor and other anticancer agents |
| JP2012520893A (ja) | 2009-03-18 | 2012-09-10 | オーエスアイ・ファーマシューティカルズ，エルエルシー | Ｅｇｆｒ阻害薬及びｉｇｆ−１ｒ阻害剤の投与を含む組み合わせ癌治療 |
| MA33198B1 (fr) | 2009-03-20 | 2012-04-02 | Genentech Inc | Anticorps anti-her di-spécifiques |
| IL264349B2 (en) | 2009-04-06 | 2024-01-01 | Wyeth Llc | Regimen comprising neratinib for the treatment of cancer |
| WO2010120386A1 (en) | 2009-04-17 | 2010-10-21 | Nektar Therapeutics | Oligomer-protein tyrosine kinase inhibitor conjugates |
| GEP20156250B (en) | 2009-06-26 | 2015-02-25 | Novartis Ag | 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
| US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
| SI2451445T1 (sl) | 2009-07-06 | 2019-07-31 | Boehringer Ingelheim International Gmbh | Postopek za sušenje BIBW2992, njegovih soli in trdnih farmacevtskih formulacij, ki obsegajo to aktivno sestavino |
| US9050341B2 (en) * | 2009-07-14 | 2015-06-09 | Natco Pharma Limited | Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| BR112012003262A8 (pt) | 2009-08-12 | 2016-05-17 | Novartis Ag | compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação |
| ES2709108T3 (es) | 2009-08-17 | 2019-04-15 | Intellikine Llc | Compuestos heterocíclicos y usos de los mismos |
| ES2564797T3 (es) | 2009-08-19 | 2016-03-29 | Eisai R&D Management Co., Ltd. | Composición farmacéutica con contenido en un derivado de quinolina |
| EA201200318A1 (ru) | 2009-08-20 | 2012-09-28 | Новартис Аг | Гетероциклические оксимы |
| US20120149661A1 (en) | 2009-08-26 | 2012-06-14 | Novartis Ag | Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators |
| EA201200471A1 (ru) | 2009-09-10 | 2012-10-30 | Новартис Аг | Простые эфирные производные бициклических гетероарилов |
| US20120220594A1 (en) | 2009-10-30 | 2012-08-30 | Bristol-Meyers Squibb Company | Methods for treating cancer in patients having igf-1r inhibitor resistance |
| EA201200651A1 (ru) | 2009-11-04 | 2012-12-28 | Новартис Аг | Гетероциклические сульфонамидные производные, применимые в качестве ингибиторов мек |
| TW201121570A (en) | 2009-11-12 | 2011-07-01 | Genentech Inc | A method of promoting dendritic spine density |
| CA2780875A1 (en) | 2009-11-13 | 2011-05-19 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
| AU2010321533A1 (en) | 2009-11-23 | 2012-05-31 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
| CN102712648A (zh) | 2009-11-25 | 2012-10-03 | 诺瓦提斯公司 | 双环杂芳基的与苯稠合的6元含氧杂环衍生物 |
| BR112012012983A2 (pt) | 2009-12-04 | 2020-09-15 | Genentech Inc | método para sintetizar um anticorpo multiespecífico, método para sintetizar um painel de anticorpos multiespecíficos, método para sintetizar um análogo de anticorpo, método para sintetizar um painel de análogos de anticorpo e composições |
| PE20121384A1 (es) | 2009-12-08 | 2012-10-13 | Novartis Ag | Derivados de sulfonamida heterociclicos |
| AU2012265844A1 (en) | 2009-12-08 | 2013-05-02 | Novartis Ag | Heterocyclic sulfonamide derivatives |
| CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| MX2012008049A (es) | 2010-01-12 | 2012-08-01 | Hoffmann La Roche | Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,. |
| WO2011090940A1 (en) | 2010-01-19 | 2011-07-28 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
| CN102146060B (zh) * | 2010-02-09 | 2013-07-03 | 陕西师范大学 | 制备吉非替尼及其中间体的方法 |
| MX2012008958A (es) | 2010-02-18 | 2012-08-23 | Genentech Inc | Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer. |
| CA2800230A1 (en) | 2010-03-04 | 2011-09-09 | Hospital District Of Southwest Finland | Method for selecting patients for treatment with an egfr inhibitor |
| US20130096104A1 (en) | 2010-03-17 | 2013-04-18 | Genentech, Inc. | Imidazopyridine compounds, compositions and methods of use |
| US20110237686A1 (en) | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc | Formulations and methods of use |
| AU2011235569B2 (en) | 2010-03-29 | 2016-06-30 | Zymeworks Bc Inc. | Antibodies with enhanced or suppressed effector function |
| TWI406853B (zh) * | 2010-04-07 | 2013-09-01 | Dev Center Biotechnology | Ｅｇｆｒ與ｖｅｇｆｒ－２雙重抑制劑及其用途與製法 |
| KR20130058672A (ko) | 2010-04-16 | 2013-06-04 | 제넨테크, 인크. | ＰＩ3Ｋ/ＡＫＴ 키나제 경로 억제제 효능에 대한 예측 바이오마커로서의 ＦＯＸＯ３ａ |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| US20130085161A1 (en) | 2010-06-17 | 2013-04-04 | Novartis Ag | Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
| EP2582680A1 (en) | 2010-06-17 | 2013-04-24 | Novartis AG | Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
| WO2011161217A2 (en) | 2010-06-23 | 2011-12-29 | Palacký University in Olomouc | Targeting of vegfr2 |
| KR101677790B1 (ko) | 2010-06-25 | 2016-11-18 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 키나제 저해 작용을 갖는 화합물의 병용에 의한 항종양제 |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| AR082418A1 (es) | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
| US20120089541A1 (en) | 2010-08-31 | 2012-04-12 | Genentech, Inc. | Biomarkers and methods of treatment |
| JP5822934B2 (ja) | 2010-09-15 | 2015-11-25 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | アザベンゾチアゾール化合物、組成物及び使用方法 |
| WO2012035078A1 (en) | 2010-09-16 | 2012-03-22 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
| JP5941916B2 (ja) | 2010-09-22 | 2016-06-29 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置 |
| WO2012065161A2 (en) | 2010-11-12 | 2012-05-18 | Scott & White Healthcare | Antibodies to tumor endothelial marker 8 |
| EP2640722B1 (en) | 2010-11-19 | 2015-11-04 | F.Hoffmann-La Roche Ag | Pyrazolopyridines and their use as tyk2 inhibitors |
| WO2012069557A1 (en) | 2010-11-24 | 2012-05-31 | Glaxo Group Limited | Multispecific antigen binding proteins targeting hgf |
| KR20130130030A (ko) | 2010-12-21 | 2013-11-29 | 노파르티스 아게 | Vps34 억제제로서의 비-헤테로아릴 화합물 |
| EP2468883A1 (en) | 2010-12-22 | 2012-06-27 | Pangaea Biotech S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
| WO2012085176A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors |
| US9134297B2 (en) | 2011-01-11 | 2015-09-15 | Icahn School Of Medicine At Mount Sinai | Method and compositions for treating cancer and related methods |
| AU2012213080B2 (en) | 2011-01-31 | 2014-03-27 | Novartis Ag | Novel heterocyclic derivatives |
| JP2014505088A (ja) | 2011-02-10 | 2014-02-27 | ノバルティス アーゲー | Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物 |
| EP2678016B1 (en) | 2011-02-23 | 2016-08-10 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
| EP2492688A1 (en) | 2011-02-23 | 2012-08-29 | Pangaea Biotech, S.A. | Molecular biomarkers for predicting response to antitumor treatment in lung cancer |
| SG10201601711SA (en) | 2011-03-04 | 2016-04-28 | Newgen Therapeutics Inc | Alkyne Substituted Quinazoline Compound And Methods Of Use |
| US20130338152A1 (en) | 2011-03-08 | 2013-12-19 | Irm Llc | Fluorophenyl bicyclic heteroaryl compounds |
| EP2683740B1 (en) | 2011-03-10 | 2018-07-04 | Omeros Corporation | Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution |
| US9295676B2 (en) | 2011-03-17 | 2016-03-29 | The Trustees Of The University Of Pennsylvania | Mutation mimicking compounds that bind to the kinase domain of EGFR |
| WO2012125913A1 (en) | 2011-03-17 | 2012-09-20 | The Trustees Of The University Of Pennsylvania | Methods and use of bifunctional enzyme-building clamp-shaped molecules |
| WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
| ES2543569T3 (es) | 2011-03-23 | 2015-08-20 | Amgen Inc. | Inhibidores duales tricíclicos condensados de CDK 4/6 y FLT3 |
| KR101762999B1 (ko) | 2011-04-18 | 2017-07-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 종양 치료제 |
| JP2014519813A (ja) | 2011-04-25 | 2014-08-21 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用 |
| GB201106870D0 (en) | 2011-04-26 | 2011-06-01 | Univ Belfast | Marker |
| EA023064B1 (ru) | 2011-04-28 | 2016-04-29 | Новартис Аг | ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ |
| CN102918029B (zh) | 2011-05-17 | 2015-06-17 | 江苏康缘药业股份有限公司 | 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途 |
| ES2705950T3 (es) | 2011-06-03 | 2019-03-27 | Eisai R&D Man Co Ltd | Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib |
| US8859586B2 (en) | 2011-06-20 | 2014-10-14 | Novartis Ag | Cyclohexyl isoquinolinone compounds |
| EP2721008B1 (en) | 2011-06-20 | 2015-04-29 | Novartis AG | Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors |
| EA201490164A1 (ru) | 2011-06-27 | 2014-04-30 | Новартис Аг | Твердые формы и соли производных тетрагидропиридопиримидина |
| TW201306866A (zh) | 2011-06-30 | 2013-02-16 | Genentech Inc | 抗－ｃ－ｍｅｔ抗體調配物 |
| WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| WO2013007765A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
| CA2844289C (en) | 2011-08-12 | 2020-01-14 | Omeros Corporation | Anti-fzd10 monoclonal antibodies and methods for their use |
| KR20140047160A (ko) | 2011-08-12 | 2014-04-21 | 에프. 호프만-라 로슈 아게 | 인다졸 화합물, 조성물 및 사용 방법 |
| WO2013025939A2 (en) | 2011-08-16 | 2013-02-21 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
| CA2842375A1 (en) | 2011-08-17 | 2013-02-21 | Erica Jackson | Neuregulin antibodies and uses thereof |
| EP3795145A3 (en) | 2011-08-17 | 2021-06-09 | Dennis M. Brown | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol |
| US20130084286A1 (en) | 2011-08-31 | 2013-04-04 | Thomas E. Januario | Diagnostic markers |
| WO2013038362A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase |
| EP2758397A1 (en) | 2011-09-20 | 2014-07-30 | F.Hoffmann-La Roche Ag | Imidazopyridine compounds, compositions and methods of use |
| CN103012290B (zh) * | 2011-09-28 | 2015-05-13 | 齐鲁制药有限公司 | 一种高纯度吉非替尼的制备方法 |
| CN104066851A (zh) | 2011-09-30 | 2014-09-24 | 基因泰克公司 | 肿瘤或肿瘤细胞中上皮或间充质表型的诊断性甲基化标志物和对egfr激酶抑制剂的响应 |
| WO2013056069A1 (en) | 2011-10-13 | 2013-04-18 | Bristol-Myers Squibb Company | Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors |
| PL2771342T3 (pl) | 2011-10-28 | 2016-11-30 | Nowe pochodne puryny i ich zastosowanie w leczeniu chorób | |
| TWI577671B (zh) | 2011-11-14 | 2017-04-11 | Sunshine Lake Pharma Co Ltd | Aminoquinazoline derivatives and salts thereof and methods of use thereof |
| CN103102345B (zh) * | 2011-11-14 | 2015-06-03 | 广东东阳光药业有限公司 | 氨基喹唑啉类衍生物及其盐和使用方法 |
| CN103102342B (zh) * | 2011-11-14 | 2014-10-29 | 广东东阳光药业有限公司 | 氨基喹唑啉类衍生物及其盐和使用方法 |
| US8969341B2 (en) | 2011-11-29 | 2015-03-03 | Novartis Ag | Pyrazolopyrrolidine compounds |
| CA2857114A1 (en) | 2011-11-30 | 2013-06-06 | Genentech, Inc. | Erbb3 mutations in cancer |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| CN103130729B (zh) * | 2011-12-05 | 2015-07-15 | 齐鲁制药有限公司 | 一种4-氯代-7-甲氧基喹唑啉-6-醇乙酸酯的制备方法 |
| CN103172576B (zh) * | 2011-12-21 | 2015-08-05 | 沈阳药科大学 | 吉非替尼的苹果酸加成盐及其制备和应用 |
| SG11201402237WA (en) | 2011-12-22 | 2014-09-26 | Novartis Ag | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives |
| US20150148377A1 (en) | 2011-12-22 | 2015-05-28 | Novartis Ag | Quinoline Derivatives |
| KR20140107578A (ko) | 2011-12-23 | 2014-09-04 | 노파르티스 아게 | Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물 |
| CA2859862A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
| KR20140104047A (ko) | 2011-12-23 | 2014-08-27 | 노파르티스 아게 | Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물 |
| EP2794590A1 (en) | 2011-12-23 | 2014-10-29 | Novartis AG | Compounds for inhibiting the interaction of bcl2 with binding partners |
| US20130178520A1 (en) | 2011-12-23 | 2013-07-11 | Duke University | Methods of treatment using arylcyclopropylamine compounds |
| AU2012355624A1 (en) | 2011-12-23 | 2014-07-17 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
| UY34591A (es) | 2012-01-26 | 2013-09-02 | Novartis Ag | Compuestos de imidazopirrolidinona |
| AU2013214254B2 (en) | 2012-01-31 | 2016-04-21 | Novartis Ag | Method of treating cancer |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| HK1203972A1 (en) | 2012-03-08 | 2015-11-06 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
| EP2752413B1 (en) | 2012-03-26 | 2016-03-23 | Fujian Institute Of Research On The Structure Of Matter, Chinese Academy Of Sciences | Quinazoline derivative and application thereof |
| CA2865082A1 (en) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
| MX371119B (es) | 2012-04-03 | 2020-01-17 | Novartis Ag | Productos de combinacion con los inhibidores de cinasa de tirosina y su uso. |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| SG10201608469RA (en) | 2012-05-16 | 2016-11-29 | Novartis Ag | Dosage regimen for a pi-3 kinase inhibitor |
| CN104321325B (zh) | 2012-05-24 | 2016-11-16 | 诺华股份有限公司 | 吡咯并吡咯烷酮化合物 |
| KR101457453B1 (ko) * | 2012-05-31 | 2014-11-04 | 주식회사 종근당 | 게피티닙의 제조방법 및 이의 제조에 사용되는 중간체 |
| AU2013274101B2 (en) | 2012-06-15 | 2017-09-07 | The Brigham And Women's Hospital, Inc. | Compositions for treating cancer and methods for making the same |
| WO2013190089A1 (en) | 2012-06-21 | 2013-12-27 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting outcome in lung cancer |
| WO2014016848A2 (en) | 2012-07-24 | 2014-01-30 | Laurus Labs Private Limited | Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof |
| US9738643B2 (en) | 2012-08-06 | 2017-08-22 | Duke University | Substituted indazoles for targeting Hsp90 |
| WO2014036022A1 (en) | 2012-08-29 | 2014-03-06 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
| JP6374392B2 (ja) | 2012-11-05 | 2018-08-15 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法 |
| TW201422625A (zh) | 2012-11-26 | 2014-06-16 | Novartis Ag | 二氫－吡啶并－□衍生物之固體形式 |
| BR112015009004A8 (pt) | 2012-12-21 | 2021-07-20 | Eisai R&D Man Co Ltd | forma amorfa de derivado de quinolina e método de produção da mesma |
| CN103073509A (zh) * | 2012-12-31 | 2013-05-01 | 广东先强药业有限公司 | 一类喹唑啉衍生物的制备方法 |
| CN103910690A (zh) * | 2013-01-06 | 2014-07-09 | 上海科胜药物研发有限公司 | 一种吉非替尼新晶型及其制备方法 |
| ES2651331T3 (es) | 2013-01-10 | 2018-01-25 | Glaxosmithkline Intellectual Property (No. 2) Limited | Inhibidores de la sintasa de ácidos grasos |
| WO2014115080A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
| US9403827B2 (en) | 2013-01-22 | 2016-08-02 | Novartis Ag | Substituted purinone compounds |
| BR122021012629B1 (pt) | 2013-02-01 | 2022-06-07 | Wellstat Therapeutics Corporation | Compostos de amina, composição compreendendo os referidos compostos e usos dos mesmos |
| WO2014128612A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Quinazolin-4-one derivatives |
| EP2958943B1 (en) | 2013-02-20 | 2019-09-11 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| CN104994879A (zh) | 2013-02-22 | 2015-10-21 | 霍夫曼-拉罗奇有限公司 | 治疗癌症和预防药物抗性的方法 |
| AU2014223548A1 (en) | 2013-02-26 | 2015-10-15 | Triact Therapeutics, Inc. | Cancer therapy |
| US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
| RS56566B1 (sr) | 2013-03-06 | 2018-02-28 | Astrazeneca Ab | Inhibitori hinazolina aktivirajućih mutantnih oblika receptora epidermalnog faktora rasta |
| KR20150123250A (ko) | 2013-03-06 | 2015-11-03 | 제넨테크, 인크. | 암 약물 내성의 치료 및 예방 방법 |
| RU2015143517A (ru) | 2013-03-13 | 2017-04-19 | Дженентек, Инк. | Пиразолсодержащие соединения и их применения |
| SG11201507477XA (en) | 2013-03-14 | 2015-10-29 | Genentech Inc | Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use |
| MX394360B (es) | 2013-03-14 | 2025-03-24 | Sumitomo Pharma Oncology Inc | Inhibidores de jak2 y alk2 y metodos para su uso. |
| KR20150127216A (ko) | 2013-03-14 | 2015-11-16 | 제넨테크, 인크. | 암의 치료 및 암 약물 내성의 예방 방법 |
| WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
| KR20150130451A (ko) | 2013-03-15 | 2015-11-23 | 제넨테크, 인크. | 암 치료 방법 및 항암제 내성 예방을 위한 방법 |
| WO2014147246A1 (en) | 2013-03-21 | 2014-09-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression |
| WO2014147631A1 (en) | 2013-03-22 | 2014-09-25 | Natco Pharma Limited | Formulation comprising gefitinib as oral suspension |
| WO2014155268A2 (en) | 2013-03-25 | 2014-10-02 | Novartis Ag | Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity |
| SG11201509278XA (en) | 2013-05-14 | 2015-12-30 | Eisai R&D Man Co Ltd | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| US20150018376A1 (en) | 2013-05-17 | 2015-01-15 | Novartis Ag | Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof |
| CN103304491A (zh) * | 2013-06-17 | 2013-09-18 | 连云港盛和生物科技有限公司 | 一种吉非替尼的制备方法 |
| KR20150001936A (ko) * | 2013-06-28 | 2015-01-07 | 제일약품주식회사 | 게피티닙의 신규한 결정형 및 이의 제조방법 |
| UY35675A (es) | 2013-07-24 | 2015-02-27 | Novartis Ag | Derivados sustituidos de quinazolin-4-ona |
| CN105683197B (zh) * | 2013-08-02 | 2019-12-27 | 亚尼塔公司 | 单独地或与其它试剂联合地使用AXL/cMET抑制剂治疗多种癌症的方法 |
| WO2015022663A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
| WO2015022664A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
| US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| US9505767B2 (en) | 2013-09-05 | 2016-11-29 | Genentech, Inc. | Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors |
| WO2015035410A1 (en) | 2013-09-09 | 2015-03-12 | Triact Therapeutic, Inc. | Cancer therapy |
| KR20160055253A (ko) | 2013-09-12 | 2016-05-17 | 할로자임, 아이엔씨 | 변형된 항-상피세포 성장인자 수용체 항체 및 이의 사용 방법 |
| JP6431920B2 (ja) | 2013-09-17 | 2018-11-28 | オービーアイ ファーマ，インコーポレイテッド | 免疫反応を誘導する炭水化物ワクチンの組成とがんの治療におけるその使用 |
| CA2918938C (en) | 2013-09-22 | 2021-05-18 | Calitor Sciences, Llc | Substituted aminopyrimidine compounds and methods of use |
| CN104513253A (zh) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
| WO2015049325A1 (en) | 2013-10-03 | 2015-04-09 | F. Hoffmann-La Roche Ag | Therapeutic inhibitors of cdk8 and uses thereof |
| MX2016004802A (es) | 2013-10-18 | 2016-07-18 | Genentech Inc | Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso. |
| TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途 |
| DK3076969T3 (da) | 2013-12-06 | 2021-11-22 | Novartis Ag | Doseringsregime for en alfa-isoform-selektiv phosphatidylinositol-3-kinase-hæmmer |
| CN105934253A (zh) | 2013-12-17 | 2016-09-07 | 豪夫迈·罗氏有限公司 | 使用pd-1轴结合拮抗剂和抗her2抗体治疗her2阳性癌症的方法 |
| KR20160099092A (ko) | 2013-12-17 | 2016-08-19 | 제넨테크, 인크. | Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법 |
| US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
| US20160361309A1 (en) | 2014-02-26 | 2016-12-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods of treating cancer patients responding to ezh2 inhibitor gsk126 |
| WO2015148531A1 (en) | 2014-03-24 | 2015-10-01 | Genentech, Inc. | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
| WO2015148714A1 (en) | 2014-03-25 | 2015-10-01 | Duke University | Heat shock protein 70 (hsp-70) receptor ligands |
| WO2015145388A2 (en) | 2014-03-27 | 2015-10-01 | Novartis Ag | Methods of treating colorectal cancers harboring upstream wnt pathway mutations |
| AU2015235880B2 (en) | 2014-03-28 | 2018-11-01 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
| HUE046767T2 (hu) | 2014-03-31 | 2020-03-30 | Hoffmann La Roche | Anti-OX40 antitestek és alkalmazási eljárások |
| JP6588461B2 (ja) | 2014-03-31 | 2019-10-09 | ジェネンテック， インコーポレイテッド | 抗血管新生剤及びｏｘ４０結合アゴニストを含む併用療法 |
| KR20160132496A (ko) | 2014-04-03 | 2016-11-18 | 인빅터스 온콜로지 피비티. 엘티디. | 초분자 조합 치료제 |
| US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| WO2015170345A1 (en) | 2014-05-09 | 2015-11-12 | Council Of Scientific & Industrial Research | Pharmaceutical cocrystals of gefitinib |
| RU2577518C2 (ru) * | 2014-06-02 | 2016-03-20 | Олег Ростиславович Михайлов | КРИСТАЛЛИЧЕСКАЯ БЕЗВОДНАЯ γ-МОДИФИКАЦИЯ 4-(3'-ХЛОР-4'-ФТОРАНИЛИНО)-7-МЕТОКСИ-6-(3-МОРФОЛИНОПРОПОКСИ)ХИНАЗОЛИНА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ |
| EP3154951A4 (en) * | 2014-06-10 | 2017-12-06 | Scinopharm (Changshu) Pharmaceuticals Ltd. | Process for preparing quinazoline derivative |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| US10195208B2 (en) | 2014-07-31 | 2019-02-05 | Novartis Ag | Combination therapy |
| SMT202200367T1 (it) | 2014-08-28 | 2022-11-18 | Eisai R&D Man Co Ltd | Derivato di chinolina a elevata purezza e metodo per la produzione dello stesso |
| WO2016036873A1 (en) | 2014-09-05 | 2016-03-10 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| TWI567063B (zh) * | 2014-09-05 | 2017-01-21 | 國立交通大學 | 用於促進癌細胞凋亡的化合物、其醫藥組成物及其用途 |
| CN107073125A (zh) | 2014-09-19 | 2017-08-18 | 基因泰克公司 | Cbp/ep300和bet抑制剂用于治疗癌症的用途 |
| CN107912040B (zh) | 2014-10-10 | 2021-04-06 | 基因泰克公司 | 作为组蛋白脱甲基酶抑制剂的吡咯烷酰胺化合物 |
| WO2016059600A1 (en) | 2014-10-17 | 2016-04-21 | Novartis Ag | Combination of ceritinib with an egfr inhibitor |
| SG11201703448QA (en) | 2014-11-03 | 2017-05-30 | Genentech Inc | Assays for detecting t cell immune subsets and methods of use thereof |
| AU2015343339A1 (en) | 2014-11-03 | 2017-06-15 | Genentech, Inc. | Methods and biomarkers for predicting efficacy and evaluation of an OX40 agonist treatment |
| SG11201703376QA (en) | 2014-11-06 | 2017-05-30 | Genentech Inc | Combination therapy comprising ox40 binding agonists and tigit inhibitors |
| WO2016077375A1 (en) | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Bromodomain inhibitors and uses thereof |
| MA40940A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| MA40943A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| CN106999583A (zh) | 2014-11-17 | 2017-08-01 | 豪夫迈·罗氏有限公司 | 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法 |
| CN107531690B (zh) | 2014-11-27 | 2020-11-06 | 基因泰克公司 | 用作CBP和/或EP300抑制剂的4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶-3-胺化合物 |
| RU2697551C2 (ru) | 2014-12-04 | 2019-08-15 | Дельта-Флай Фарма, Инк. | Новые производные peg |
| WO2016096999A1 (en) | 2014-12-19 | 2016-06-23 | Synthon B.V. | Pharmaceutical composition comprising gefifinib |
| AU2015369624A1 (en) | 2014-12-23 | 2017-06-08 | Genentech, Inc. | Compositions and methods for treating and diagnosing chemotherapy-resistant cancers |
| KR20170095893A (ko) | 2014-12-24 | 2017-08-23 | 제넨테크, 인크. | 방광암에 대한 치료, 진단, 및 예후 방법 |
| WO2016109546A2 (en) | 2014-12-30 | 2016-07-07 | Genentech, Inc. | Methods and compositions for prognosis and treatment of cancers |
| DK3242666T5 (da) | 2015-01-06 | 2025-01-20 | Arena Pharm Inc | Forbindelsee til anvendelse i behandling af tilstande, der er forbundet med SIP1-receptoren |
| CA2972592A1 (en) | 2015-01-08 | 2016-07-14 | The Board Of Trustees Of The Leland Stanford Junior University | Factors and cells that provide for induction of bone, bone marrow, and cartilage |
| EP3242875B1 (en) | 2015-01-09 | 2022-02-23 | Genentech, Inc. | 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors |
| WO2016112298A1 (en) | 2015-01-09 | 2016-07-14 | Genentech, Inc. | Pyridazinone derivatives and their use in the treatment of cancer |
| EP3242872B1 (en) | 2015-01-09 | 2019-07-03 | Genentech, Inc. | (piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer |
| KR101635724B1 (ko) * | 2015-01-28 | 2016-07-05 | 일동제약주식회사 | 게피티닙의 개선된 제조방법 |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| CN107531692B (zh) | 2015-01-29 | 2020-12-25 | 基因泰克公司 | 治疗化合物及其用途 |
| WO2016123387A1 (en) | 2015-01-30 | 2016-08-04 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| MA41598A (fr) | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| DK3263106T3 (da) | 2015-02-25 | 2024-01-08 | Eisai R&D Man Co Ltd | Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat |
| KR20250020678A (ko) | 2015-03-04 | 2025-02-11 | 머크 샤프 앤드 돔 엘엘씨 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| ES2775614T3 (es) * | 2015-03-20 | 2020-07-27 | Chai Tai Tianqing Pharmaceutical Group Co Ltd | Sales de derivado de quinazolina y método de preparación de las mismas |
| AU2016246695A1 (en) | 2015-04-07 | 2017-10-26 | Genentech, Inc. | Antigen binding complex having agonistic activity and methods of use |
| KR20180008449A (ko) | 2015-05-12 | 2018-01-24 | 제넨테크, 인크. | 암에 대한 치료 및 진단 방법 |
| ES2789500T5 (es) | 2015-05-29 | 2023-09-20 | Hoffmann La Roche | Procedimientos terapéuticos y de diagnóstico para el cáncer |
| KR20180025888A (ko) | 2015-06-08 | 2018-03-09 | 제넨테크, 인크. | 항-ox40 항체 및 pd-1 축 결합 길항제를 사용하여 암을 치료하는 방법 |
| CA2985483A1 (en) | 2015-06-08 | 2016-12-15 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies |
| ES2886107T3 (es) | 2015-06-16 | 2021-12-16 | Prism Biolab Co Ltd | Antineoplásico |
| CN107771076A (zh) | 2015-06-17 | 2018-03-06 | 豪夫迈·罗氏有限公司 | 使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法 |
| JP6838744B2 (ja) | 2015-06-22 | 2021-03-03 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩 |
| EP3317323B1 (en) | 2015-07-01 | 2021-05-26 | California Institute of Technology | Cationic mucic acid polymer-based delivery systems |
| US20180230431A1 (en) | 2015-08-07 | 2018-08-16 | Glaxosmithkline Intellectual Property Development Limited | Combination Therapy |
| CA2994925C (en) | 2015-08-20 | 2023-08-29 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| WO2017033019A1 (en) | 2015-08-26 | 2017-03-02 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii (Cnio) | Condensed tricyclic compounds as protein kinase inhibitors |
| AR105910A1 (es) | 2015-09-04 | 2017-11-22 | Obi Pharma Inc | Matrices de glicano y método de uso |
| WO2017044434A1 (en) | 2015-09-11 | 2017-03-16 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
| GB201516905D0 (en) | 2015-09-24 | 2015-11-11 | Stratified Medical Ltd | Treatment of Neurodegenerative diseases |
| LT3353210T (lt) | 2015-09-25 | 2025-01-27 | F. Hoffmann-La Roche Ag | Antikūnai prieš tigit ir jų naudojimo būdai |
| CN105250228B (zh) * | 2015-10-12 | 2017-10-24 | 山东罗欣药业集团股份有限公司 | 一种吉非替尼的片剂及其原料的制备方法 |
| WO2017077445A1 (en) | 2015-11-02 | 2017-05-11 | Novartis Ag | Dosage regimen for a phosphatidylinositol 3-kinase inhibitor |
| AU2016362774A1 (en) | 2015-12-01 | 2018-05-31 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
| AU2016369528B2 (en) | 2015-12-16 | 2021-04-22 | Genentech, Inc. | Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer |
| US10259805B2 (en) | 2015-12-30 | 2019-04-16 | Synthon B.V. | Process for making crystalline form a of gefitinib |
| CN105503748A (zh) * | 2015-12-31 | 2016-04-20 | 哈药集团技术中心 | 一种吉非替尼的制备方法 |
| CN108368179B (zh) | 2016-01-08 | 2022-08-23 | 豪夫迈·罗氏有限公司 | 使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法 |
| AU2017225854B2 (en) | 2016-02-29 | 2020-11-19 | Foundation Medicine, Inc. | Therapeutic and diagnostic methods for cancer |
| BR112018070097A2 (pt) | 2016-03-29 | 2019-02-12 | Obi Pharma, Inc. | anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| WO2017180864A1 (en) | 2016-04-14 | 2017-10-19 | Genentech, Inc. | Anti-rspo3 antibodies and methods of use |
| AU2017250296A1 (en) | 2016-04-15 | 2018-11-01 | Genentech, Inc. | Methods for monitoring and treating cancer |
| JP2019515670A (ja) | 2016-04-15 | 2019-06-13 | ジェネンテック， インコーポレイテッド | がんをモニタリングし治療するための方法 |
| WO2017180581A1 (en) | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| IL262296B2 (en) | 2016-04-22 | 2024-09-01 | Obi Pharma Inc | Cancer immunotherapy by immune activation or immune modulation via globo series antigens |
| WO2017184956A1 (en) | 2016-04-22 | 2017-10-26 | Duke University | Compounds and methods for targeting hsp90 |
| US20190151346A1 (en) | 2016-05-10 | 2019-05-23 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
| KR101796684B1 (ko) * | 2016-05-19 | 2017-11-10 | 건국대학교 산학협력단 | 케라틴 8 인산화 억제제를 포함하는 황반변성 예방 또는 치료용 약학 조성물 및 황반변성 치료제의 스크리닝 방법 |
| JP7160688B2 (ja) | 2016-05-24 | 2022-10-25 | ジェネンテック， インコーポレイテッド | Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用 |
| EP3464286B1 (en) | 2016-05-24 | 2021-08-18 | Genentech, Inc. | Pyrazolopyridine derivatives for the treatment of cancer |
| CN106045980B (zh) * | 2016-06-03 | 2017-11-03 | 江苏开放大学 | 一种喹唑啉衍生物及其制备方法 |
| EP3469099A1 (en) | 2016-06-08 | 2019-04-17 | F. Hoffmann-La Roche AG | Diagnostic and therapeutic methods for cancer |
| US11365256B2 (en) | 2016-06-08 | 2022-06-21 | Xencor, Inc. | Methods and compositions for inhibiting CD32B expressing cells in IGG4-related diseases |
| CA3032049C (en) | 2016-07-27 | 2023-11-07 | Obi Pharma, Inc. | Immunogenic/therapeutic glycan compositions and uses thereof |
| JP7121724B2 (ja) | 2016-07-29 | 2022-08-18 | オービーアイ ファーマ，インコーポレイテッド | ヒト抗体、医薬組成物及び方法 |
| WO2018025221A1 (en) | 2016-08-04 | 2018-02-08 | Glaxosmithkline Intellectual Property Development Limited | Anti-icos and anti-pd-1 antibody combination therapy |
| CN109963871A (zh) | 2016-08-05 | 2019-07-02 | 豪夫迈·罗氏有限公司 | 具有激动活性的多价及多表位抗体以及使用方法 |
| WO2018029124A1 (en) | 2016-08-08 | 2018-02-15 | F. Hoffmann-La Roche Ag | Therapeutic and diagnostic methods for cancer |
| WO2018039203A1 (en) | 2016-08-23 | 2018-03-01 | Oncopep, Inc. | Peptide vaccines and durvalumab for treating multiple myeloma |
| WO2018039205A1 (en) | 2016-08-23 | 2018-03-01 | Oncopep, Inc. | Peptide vaccines and durvalumab for treating breast cancer |
| CN106432202B (zh) * | 2016-09-22 | 2019-04-02 | 郑州大学第一附属医院 | 喹唑啉类衍生物及其应用 |
| WO2018060833A1 (en) | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
| WO2018064076A1 (en) | 2016-09-27 | 2018-04-05 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules |
| US10927083B2 (en) | 2016-09-29 | 2021-02-23 | Duke University | Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase |
| US10207998B2 (en) | 2016-09-29 | 2019-02-19 | Duke University | Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof |
| MX2019003934A (es) | 2016-10-06 | 2019-07-10 | Genentech Inc | Métodos terapéuticos y de diagnóstico para el cáncer. |
| WO2018078143A1 (en) | 2016-10-28 | 2018-05-03 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy |
| EP3532091A2 (en) | 2016-10-29 | 2019-09-04 | H. Hoffnabb-La Roche Ag | Anti-mic antibidies and methods of use |
| JP2019535731A (ja) | 2016-11-21 | 2019-12-12 | オービーアイ ファーマ，インコーポレイテッド | コンジュゲートさせた生物学的分子、医薬組成物及び方法 |
| HRP20211642T1 (hr) | 2016-12-22 | 2022-01-21 | Amgen Inc. | Derivati benzizotiazola, izotiazolo[3,4-b]piridina, kinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao inhibitori kras g12c za liječenje raka pluća, gušterače ili kolorektalnog karcinoma |
| RU2750539C2 (ru) | 2017-02-08 | 2021-06-29 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Фармацевтическая композиция для лечения опухоли |
| PL3589754T3 (pl) | 2017-03-01 | 2023-10-09 | F. Hoffmann-La Roche Ag | Sposoby diagnostyczne i terapeutyczne w chorobach nowotworowych |
| US9980967B1 (en) | 2017-03-16 | 2018-05-29 | National Chiao Tung University | Method for overcoming drug resistance of EGFR mutation and cancerous stemness of human non-small cell lung carcinoma |
| KR20190136076A (ko) | 2017-04-13 | 2019-12-09 | 에프. 호프만-라 로슈 아게 | 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제 |
| CA3061888A1 (en) | 2017-05-16 | 2018-11-22 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| MX2020000604A (es) | 2017-07-21 | 2020-09-10 | Genentech Inc | Métodos terapéuticos y de diagnóstico para el cáncer. |
| AU2018316343B2 (en) | 2017-08-11 | 2025-06-12 | Genentech, Inc. | Anti-CD8 antibodies and uses thereof |
| CA3073073A1 (en) | 2017-09-08 | 2019-03-14 | F. Hoffmann-La Roche Ag | Diagnostic and therapeutic methods for cancer |
| WO2019051291A1 (en) | 2017-09-08 | 2019-03-14 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
| FI3688032T3 (fi) | 2017-09-26 | 2025-12-09 | Cero Therapeutics Holdings Inc | Kimeerisiä nielaisureseptorimolekyylejä ja käyttömenetelmiä |
| WO2019083962A1 (en) | 2017-10-24 | 2019-05-02 | Oncopep, Inc. | PEPTIDE AND PEMBROLIZUMAB VACCINES FOR THE TREATMENT OF BREAST CANCER |
| WO2019083960A1 (en) | 2017-10-24 | 2019-05-02 | Oncopep, Inc. | PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA |
| WO2019084395A1 (en) | 2017-10-27 | 2019-05-02 | University Of Virginia Patent Foundation | COMPOUNDS AND METHODS FOR REGULATING, LIMITING OR INHIBITING AVIL EXPRESSION |
| CN109721552B (zh) * | 2017-10-30 | 2022-09-20 | 上海北卡医药技术有限公司 | 一种吉非替尼的制备方法 |
| TW201923089A (zh) | 2017-11-06 | 2019-06-16 | 美商建南德克公司 | 癌症之診斷及治療方法 |
| JP7254076B2 (ja) | 2017-11-19 | 2023-04-07 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | 置換ヘテロアリール化合物及び使用方法 |
| CA3085593A1 (en) | 2017-12-18 | 2019-06-27 | Sterngreene, Inc. | Pyrimidine compounds useful as tyrosine kinase inhibitors |
| US11602534B2 (en) | 2017-12-21 | 2023-03-14 | Hefei Institutes Of Physical Science, Chinese Academy Of Sciences | Pyrimidine derivative kinase inhibitors |
| SG11202006441SA (en) | 2018-01-15 | 2020-08-28 | Epiaxis Therapeutics Pty Ltd | Agents and methods for predicting response to therapy |
| US10751339B2 (en) | 2018-01-20 | 2020-08-25 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
| CN112312909B (zh) | 2018-01-26 | 2024-07-02 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| CA3088198A1 (en) | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| MA51673B1 (fr) | 2018-01-26 | 2025-10-31 | Exelixis, Inc. | Composés pour le traitement des troubles dépendants de kinases |
| TWI874309B (zh) | 2018-02-26 | 2025-03-01 | 美商建南德克公司 | 用於抗tigit拮抗劑抗體及抗pd-l1拮抗劑抗體治療之投藥 |
| CN112218886A (zh) | 2018-03-28 | 2021-01-12 | 森罗治疗公司 | 嵌合吞噬受体的表达载体、基因修饰的宿主细胞及其用途 |
| KR20210024443A (ko) | 2018-03-28 | 2021-03-05 | 세로 테라퓨틱스, 인코포레이티드 | 세포 면역요법 조성물 및 이의 용도 |
| WO2019191334A1 (en) | 2018-03-28 | 2019-10-03 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| MX2020010437A (es) | 2018-04-05 | 2021-01-29 | Sumitomo Pharma Oncology Inc | Inhibidores de axl cinasa y uso de los mismos. |
| CA3099118A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| JP7266043B2 (ja) | 2018-05-04 | 2023-04-27 | アムジエン・インコーポレーテツド | ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法 |
| CN108395410A (zh) * | 2018-05-09 | 2018-08-14 | 日照市普达医药科技有限公司 | 一种苯胺喹唑啉化合物及其在抗肿瘤药物中的应用 |
| JP7361720B2 (ja) | 2018-05-10 | 2023-10-16 | アムジエン・インコーポレーテツド | がんの治療のためのｋｒａｓ ｇ１２ｃ阻害剤 |
| WO2019226514A2 (en) | 2018-05-21 | 2019-11-28 | Nanostring Technologies, Inc. | Molecular gene signatures and methods of using same |
| EP3802535B1 (en) | 2018-06-01 | 2022-12-14 | Amgen, Inc | Kras g12c inhibitors and methods of using the same |
| CN113194752A (zh) | 2018-06-01 | 2021-07-30 | 康奈尔大学 | Pi3k相关疾病或病症的组合疗法 |
| ES2987794T3 (es) | 2018-06-06 | 2024-11-18 | Arena Pharm Inc | Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1 |
| JP7357644B2 (ja) | 2018-06-11 | 2023-10-06 | アムジエン・インコーポレーテツド | がんを処置するためのｋｒａｓ ｇ１２ｃ阻害剤 |
| AU2019336588B2 (en) | 2018-06-12 | 2022-07-28 | Amgen Inc. | KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer |
| CA3099440A1 (en) | 2018-06-13 | 2019-12-19 | California Institute Of Technology | Nanoparticles for crossing the blood brain barrier and methods of treatment using the same |
| AU2019288728A1 (en) | 2018-06-23 | 2021-01-14 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
| TWI853822B (zh) | 2018-06-27 | 2024-09-01 | 台灣浩鼎生技股份有限公司 | 用於糖蛋白工程的糖苷合成酶變體及其使用方法 |
| JP2021530502A (ja) | 2018-07-18 | 2021-11-11 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト、代謝拮抗剤、及びプラチナ製剤で肺がんを治療する方法 |
| US12220423B2 (en) | 2018-07-24 | 2025-02-11 | Hygia Pharmaceuticals, Llc | Compounds, derivatives, and analogs for cancer |
| EP3826684A4 (en) | 2018-07-26 | 2022-04-06 | Sumitomo Dainippon Pharma Oncology, Inc. | METHODS OF TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE IN THE SAME |
| CN112805267B (zh) | 2018-09-03 | 2024-03-08 | 豪夫迈·罗氏有限公司 | 用作tead调节剂的甲酰胺和磺酰胺衍生物 |
| AU2019342099A1 (en) | 2018-09-19 | 2021-04-08 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
| WO2020061349A1 (en) | 2018-09-21 | 2020-03-26 | Genentech, Inc. | Diagnostic methods for triple-negative breast cancer |
| AU2019352741A1 (en) | 2018-10-04 | 2021-05-06 | Assistance Publique-Hôpitaux De Paris (Aphp) | EGFR inhibitors for treating keratodermas |
| AU2019362972A1 (en) | 2018-10-17 | 2021-05-20 | The University Of Queensland | Epigenetic biomarker and uses therefor |
| CA3116324A1 (en) | 2018-10-18 | 2020-04-23 | Genentech, Inc. | Diagnostic and therapeutic methods for sarcomatoid kidney cancer |
| JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法 |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| AU2019384118B2 (en) | 2018-11-19 | 2025-06-12 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| EP3898626A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| EP3898615A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
| AU2019403486B2 (en) | 2018-12-20 | 2025-04-24 | Amgen Inc. | KIF18A inhibitors |
| ES2997190T3 (en) | 2018-12-20 | 2025-02-14 | Amgen Inc | Heteroaryl amides useful as kif18a inhibitors |
| CA3123042A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
| CA3123227A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
| AU2019407426A1 (en) | 2018-12-21 | 2021-07-22 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
| WO2020160365A1 (en) | 2019-02-01 | 2020-08-06 | Glaxosmithkline Intellectual Property Development Limited | Belantamab mafodotin in combination with pembrolizumab for treating cancer |
| CN113396230A (zh) | 2019-02-08 | 2021-09-14 | 豪夫迈·罗氏有限公司 | 癌症的诊断和治疗方法 |
| JP7520389B2 (ja) | 2019-02-27 | 2024-07-23 | エピアクシス セラピューティクス プロプライエタリー リミテッド | Ｔ細胞機能を評価して治療法に対する応答を予測するための方法および薬剤 |
| WO2020176748A1 (en) | 2019-02-27 | 2020-09-03 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies |
| CA3130080A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| AU2020232616A1 (en) | 2019-03-01 | 2021-09-09 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
| WO2020223233A1 (en) | 2019-04-30 | 2020-11-05 | Genentech, Inc. | Prognostic and therapeutic methods for colorectal cancer |
| CA3133821A1 (en) | 2019-05-03 | 2020-11-12 | Genentech, Inc. | Methods of treating cancer with an anti-pd-l1 antibody |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| NZ782284A (en) | 2019-05-21 | 2024-11-29 | Amgen Inc | Solid state forms |
| CA3143211A1 (en) | 2019-06-26 | 2020-12-30 | Glaxosmithkline Intellectual Property Development Limited | Il1rap binding proteins |
| CN112300279A (zh) | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | 针对抗cd73抗体和变体的方法和组合物 |
| CA3147451A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| CN114401953A (zh) | 2019-08-02 | 2022-04-26 | 美国安进公司 | Kif18a抑制剂 |
| CN114391012B (zh) | 2019-08-02 | 2025-10-31 | 美国安进公司 | 作为kif18a抑制剂的吡啶衍生物 |
| US20220289724A1 (en) | 2019-08-02 | 2022-09-15 | Amgen Inc. | Kif18a inhibitors |
| US20230192853A1 (en) | 2019-09-04 | 2023-06-22 | Genentech, Inc. | Cd8 binding agents and uses thereof |
| WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
| WO2021046293A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab |
| US12371428B2 (en) | 2019-09-26 | 2025-07-29 | Exelixis, Inc. | Pyridone compounds and methods of use |
| CA3151406A1 (en) | 2019-09-27 | 2021-04-01 | Raymond D. Meng | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
| US20240058446A1 (en) | 2019-10-03 | 2024-02-22 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| EP4048671A1 (en) | 2019-10-24 | 2022-08-31 | Amgen Inc. | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer |
| CN114728936A (zh) | 2019-10-29 | 2022-07-08 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的双功能化合物 |
| KR20250175006A (ko) | 2019-11-04 | 2025-12-15 | 레볼루션 메디슨즈, 인크. | Ras 억제제 |
| CA3159559A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| CN114867735A (zh) | 2019-11-04 | 2022-08-05 | 锐新医药公司 | Ras抑制剂 |
| CA3155922A1 (en) | 2019-11-06 | 2021-05-14 | Huang Huang | Diagnostic and therapeutic methods for treatment of hematologic cancers |
| TW202128688A (zh) | 2019-11-08 | 2021-08-01 | 美商銳新醫藥公司 | 雙環雜芳基化合物及其用途 |
| US20210161897A1 (en) | 2019-11-12 | 2021-06-03 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| JP7629916B2 (ja) | 2019-11-13 | 2025-02-14 | ジェネンテック， インコーポレイテッド | 治療用化合物および使用方法 |
| US20220395553A1 (en) | 2019-11-14 | 2022-12-15 | Cohbar, Inc. | Cxcr4 antagonist peptides |
| WO2021097212A1 (en) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
| EP4058432A1 (en) | 2019-11-14 | 2022-09-21 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
| CN114980976A (zh) | 2019-11-27 | 2022-08-30 | 锐新医药公司 | 共价ras抑制剂及其用途 |
| TWI897903B (zh) | 2019-12-13 | 2025-09-21 | 美商建南德克公司 | 抗ly6g6d抗體及其使用方法 |
| TW202136276A (zh) | 2019-12-20 | 2021-10-01 | 美商艾瑞斯卡公司 | 三環吡啶酮及嘧啶酮 |
| AU2021206217A1 (en) | 2020-01-07 | 2022-09-01 | Revolution Medicines, Inc. | SHP2 inhibitor dosing and methods of treating cancer |
| KR20220130190A (ko) | 2020-01-20 | 2022-09-26 | 아스트라제네카 아베 | 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제 |
| WO2021194481A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
| WO2022050954A1 (en) | 2020-09-04 | 2022-03-10 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
| CA3165187A1 (en) | 2020-01-27 | 2021-08-05 | Catherine LAI | Methods for treatment of cancer with an anti-tigit antagonist antibody |
| CN115038466A (zh) | 2020-01-28 | 2022-09-09 | 葛兰素史密斯克莱知识产权发展有限公司 | 联合治疗及其用途和方法 |
| WO2021177980A1 (en) | 2020-03-06 | 2021-09-10 | Genentech, Inc. | Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist |
| WO2021233534A1 (en) | 2020-05-20 | 2021-11-25 | Pvac Medical Technologies Ltd | Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof |
| WO2021185844A1 (en) | 2020-03-16 | 2021-09-23 | Pvac Medical Technologies Ltd | Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof |
| JP2023517393A (ja) * | 2020-03-17 | 2023-04-25 | メッドシャイン ディスカバリー インコーポレイテッド | タンパク質分解調整剤およびその使用方法 |
| CN115698717A (zh) | 2020-04-03 | 2023-02-03 | 基因泰克公司 | 癌症的治疗和诊断方法 |
| WO2021211776A1 (en) | 2020-04-15 | 2021-10-21 | California Institute Of Technology | Thermal control of t-cell immunotherapy through molecular and physical actuation |
| WO2021222167A1 (en) | 2020-04-28 | 2021-11-04 | Genentech, Inc. | Methods and compositions for non-small cell lung cancer immunotherapy |
| CN113801068B (zh) * | 2020-06-15 | 2024-10-11 | 山东新时代药业有限公司 | 一种吉非替尼的有机酸盐 |
| CN115916182A (zh) | 2020-06-16 | 2023-04-04 | 基因泰克公司 | 用于治疗三阴性乳腺癌的方法和组合物 |
| MX2022016355A (es) | 2020-06-18 | 2023-04-03 | Revolution Medicines Inc | Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras. |
| JP2023531200A (ja) | 2020-06-18 | 2023-07-21 | ジェネンテック， インコーポレイテッド | 抗ｔｉｇｉｔ抗体及びｐｄ－１軸結合アンタゴニストを用いた治療 |
| WO2022002874A1 (en) | 2020-06-30 | 2022-01-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery |
| WO2022002873A1 (en) | 2020-06-30 | 2022-01-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies |
| US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
| JP2023536602A (ja) | 2020-08-03 | 2023-08-28 | ジェネンテック， インコーポレイテッド | リンパ腫のための診断及び治療方法 |
| JP2023536346A (ja) | 2020-08-05 | 2023-08-24 | エリプシーズ ファーマ リミテッド | シクロデキストリン含有ポリマートポイソメラーゼ阻害剤コンジュゲートおよびｐａｒｐ阻害剤を用いた癌の処置 |
| WO2022036146A1 (en) | 2020-08-12 | 2022-02-17 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| WO2022036285A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase |
| WO2022036287A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Anti-cd72 chimeric receptors and uses thereof |
| WO2022036265A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Chimeric tim receptors and uses thereof |
| CN116847887A (zh) | 2020-08-27 | 2023-10-03 | 伊诺西治疗公司 | 治疗自身免疫性疾病和癌症的方法和组合物 |
| US11999964B2 (en) | 2020-08-28 | 2024-06-04 | California Institute Of Technology | Synthetic mammalian signaling circuits for robust cell population control |
| KR20230081726A (ko) | 2020-09-03 | 2023-06-07 | 레볼루션 메디슨즈, 인크. | Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도 |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| CA3196277A1 (en) | 2020-09-23 | 2022-03-31 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| AU2021358031A1 (en) | 2020-10-05 | 2023-05-04 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| TW202237638A (zh) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法 |
| WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| CA3203111A1 (en) | 2020-12-22 | 2022-06-30 | Kailiang Wang | Sos1 inhibitors and uses thereof |
| CN112321814B (zh) * | 2020-12-30 | 2021-03-23 | 广州初曲科技有限公司 | 一种吉非替尼艾地苯醌轭合物的制备及用途 |
| JP2024506339A (ja) | 2021-02-12 | 2024-02-13 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療のための二環式テトラヒドロアゼピン誘導体 |
| CA3211063A1 (en) | 2021-02-19 | 2022-08-25 | Exelixis, Inc. | Pyridone compounds and methods of use |
| BR112023017213A2 (pt) | 2021-02-26 | 2023-11-21 | Kelonia Therapeutics Inc | Vetores lentivirais direcionados a linfócitos |
| TW202309052A (zh) | 2021-05-05 | 2023-03-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ｒａｓ阻害剤及びその使用 |
| CN117616031A (zh) | 2021-05-05 | 2024-02-27 | 锐新医药公司 | 用于治疗癌症的ras抑制剂 |
| CA3221390A1 (en) | 2021-05-25 | 2022-12-01 | Erasca, Inc. | Sulfur-containing heteroaromatic tricyclic kras inhibitors |
| WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
| CN113527266A (zh) * | 2021-06-23 | 2021-10-22 | 上海健康医学院 | 一种靶向fap的双氧水响应的前药及其制备方法与应用 |
| CN113336742B (zh) | 2021-06-29 | 2022-05-10 | 山东金吉利新材料有限公司 | 一种马来酸吡咯替尼中间体的合成方法 |
| WO2023001894A1 (en) | 2021-07-20 | 2023-01-26 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their preparation, and uses |
| KR20240119868A (ko) | 2021-07-28 | 2024-08-06 | 세로 테라퓨틱스, 인코포레이티드 | 키메라 tim4 수용체 및 이의 용도 |
| EP4384522A1 (en) | 2021-08-10 | 2024-06-19 | Erasca, Inc. | Selective kras inhibitors |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN113845485B (zh) * | 2021-10-22 | 2023-03-14 | 湖南中医药大学 | 氨基酸衍生物及其制备方法和应用 |
| US12275745B2 (en) | 2021-11-24 | 2025-04-15 | Genentech, Inc. | Therapeutic compounds and methods of use |
| WO2023097195A1 (en) | 2021-11-24 | 2023-06-01 | Genentech, Inc. | Therapeutic indazole compounds and methods of use in the treatment of cancer |
| WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| WO2023144127A1 (en) | 2022-01-31 | 2023-08-03 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon administration, and uses |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| EP4490146A1 (en) | 2022-03-07 | 2025-01-15 | Amgen Inc. | A process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile |
| JP2025510572A (ja) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | 免疫不応性肺癌を治療するための方法 |
| AU2023246862A1 (en) | 2022-03-31 | 2024-10-31 | Astrazeneca Ab | Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer |
| EP4504780A1 (en) | 2022-04-01 | 2025-02-12 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| KR20250008898A (ko) | 2022-05-11 | 2025-01-16 | 제넨테크, 인크. | 항-fcrh5/항-cd3 이중특이성 항체로 치료하기 위한 투약법 |
| CN119856056A (zh) | 2022-06-07 | 2025-04-18 | 基因泰克公司 | 用于确定包括抗pd-l1拮抗剂和抗tight拮抗剂抗体的肺癌治疗的疗效的方法 |
| IL317476A (en) | 2022-06-10 | 2025-02-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| IL317733A (en) | 2022-06-27 | 2025-02-01 | Astrazeneca Ab | Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for cancer treatment |
| KR20250039386A (ko) | 2022-07-13 | 2025-03-20 | 제넨테크, 인크. | 항-fcrh5/항-cd3 이중특이적 항체를 이용한 치료를 위한 투약법 |
| JP2025523845A (ja) | 2022-07-19 | 2025-07-25 | ジェネンテック， インコーポレイテッド | 抗ｆｃｒｈ５／抗ｃｄ３二重特異性抗体による処置のための投薬 |
| EP4565684A1 (en) | 2022-08-02 | 2025-06-11 | National University Corporation Hokkaido University | Methods of improving cellular therapy with organelle complexes |
| AR130167A1 (es) | 2022-08-11 | 2024-11-13 | Hoffmann La Roche | Derivados bicíclicos de tetrahidroazepina |
| CR20250043A (es) | 2022-08-11 | 2025-03-25 | Hoffmann La Roche | Derivados bicíclicos de tetrahidrotiazepina |
| IL318163A (en) | 2022-08-11 | 2025-03-01 | Hoffmann La Roche | TETRAHYDROTHIAZEPINE DERIVATIVES CYCLES |
| AR130169A1 (es) | 2022-08-11 | 2024-11-13 | Hoffmann La Roche | Derivados de tetrahidrotiazepina bicíclicos |
| CN120359029A (zh) | 2022-10-14 | 2025-07-22 | 黑钻治疗公司 | 使用异喹啉或6-氮杂-喹啉衍生物治疗癌症的方法 |
| JP2025538859A (ja) | 2022-10-21 | 2025-12-02 | 公益財団法人川崎市産業振興財団 | 非吸着性またはスーパーステルス小胞 |
| JP2025535944A (ja) | 2022-10-24 | 2025-10-30 | エイジーエス・セラピューティクス・ソシエテ・パール・アクシオン・サンプリフィエ | 微細藻類由来の細胞外小胞、鼻腔内投与時のそれらの生体内分布、及びそれらの使用 |
| TW202426505A (zh) | 2022-10-25 | 2024-07-01 | 美商建南德克公司 | 癌症之治療及診斷方法 |
| TW202434206A (zh) | 2023-02-17 | 2024-09-01 | 美商伊瑞斯卡公司 | Ｋｒａｓ抑制劑 |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AU2024243852A1 (en) | 2023-04-07 | 2025-11-06 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| WO2024216016A1 (en) | 2023-04-14 | 2024-10-17 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| US20240352038A1 (en) | 2023-04-14 | 2024-10-24 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2024233341A1 (en) | 2023-05-05 | 2024-11-14 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| CN121285742A (zh) | 2023-06-08 | 2026-01-06 | 基因泰克公司 | 用于淋巴瘤的诊断和治疗方法的巨噬细胞特征 |
| WO2025024257A1 (en) | 2023-07-21 | 2025-01-30 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025049277A1 (en) | 2023-08-25 | 2025-03-06 | Genentech, Inc. | Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025137507A1 (en) | 2023-12-22 | 2025-06-26 | Regor Pharmaceuticals, Inc. | Sos1 inhibitors and uses thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025176843A1 (en) | 2024-02-21 | 2025-08-28 | Ags Therapeutics Sas | Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3266990A (en) * | 1963-09-24 | 1966-08-16 | Warner Lambert Pharmaceutical | Derivatives of quinazoline |
| JPS5538325A (en) * | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
| US4343940A (en) * | 1979-02-13 | 1982-08-10 | Mead Johnson & Company | Anti-tumor quinazoline compounds |
| GB2160201B (en) * | 1984-06-14 | 1988-05-11 | Wyeth John & Brother Ltd | Quinazoline and cinnoline derivatives |
| EP0326307B1 (en) * | 1988-01-23 | 1994-08-17 | Kyowa Hakko Kogyo Co., Ltd. | Novel pyridazinone derivatives and pharmaceutical preparations containing them |
| IL89029A (en) * | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
| CZ387292A3 (en) * | 1991-02-20 | 1994-04-13 | Pfizer | 2,4-diaminoquinazoline derivatives, process of their preparation and use as substances for increasing anti-tumorous activity |
| US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| ES2108120T3 (es) * | 1991-05-10 | 1997-12-16 | Rhone Poulenc Rorer Int | Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf. |
| NZ243082A (en) * | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| GB9323290D0 (en) * | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| GB9314884D0 (en) * | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
| GB9314893D0 (en) * | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| WO1995006648A1 (fr) * | 1993-09-03 | 1995-03-09 | Kyowa Hakko Kogyo Co., Ltd. | Derive d'imidazoquinazoline |
| US5409000A (en) * | 1993-09-14 | 1995-04-25 | Cardiac Pathways Corporation | Endocardial mapping and ablation system utilizing separately controlled steerable ablation catheter with ultrasonic imaging capabilities and method |
| GB9325217D0 (en) * | 1993-12-09 | 1994-02-09 | Zeneca Ltd | Pyrimidine derivatives |
| US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| IL112248A0 (en) * | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| CZ288955B6 (cs) * | 1994-02-23 | 2001-10-17 | Pfizer Inc. | Substituované chinazolinové deriváty, jejich pouľití a farmaceutické prostředky na jejich bázi |
| AU2096895A (en) * | 1994-03-07 | 1995-09-25 | Sugen, Incorporated | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| ATE159257T1 (de) * | 1994-05-03 | 1997-11-15 | Ciba Geigy Ag | Pyrrolopyrimidinderivate mit antiproliferativer wirkung |
| GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| TW321649B (enExample) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| DE19510019A1 (de) * | 1995-03-20 | 1996-09-26 | Thomae Gmbh Dr K | Imidazo[4,5-g]chinazoline, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| WO1996029331A1 (de) * | 1995-03-20 | 1996-09-26 | Dr. Karl Thomae Gmbh | Imidazochinazoline, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| DE122005000053I2 (de) * | 1995-03-30 | 2008-01-17 | Pfizer Prod Inc | Chinazolinderivate |
| ES2150113T3 (es) * | 1995-04-03 | 2000-11-16 | Novartis Ag | Derivados de pirazol y procedimientos para la preparacion de los mismos. |
| GB9508537D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508535D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
| AU5343096A (en) * | 1995-04-27 | 1996-11-18 | Zeneca Limited | Quinazoline derivatives |
| GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| IL117923A (en) * | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| KR100256707B1 (ko) * | 1995-05-12 | 2000-05-15 | 해피 페너 | 데아자푸린 유도체; 새로운 부류의 crf1 특이 리간드 |
| JP3290666B2 (ja) * | 1995-06-07 | 2002-06-10 | ファイザー・インコーポレーテッド | 複素環式の縮合環ピリミジン誘導体 |
| JPH11507052A (ja) * | 1995-06-07 | 1999-06-22 | スージェン・インコーポレーテッド | キナゾリンおよび医薬組成物 |
| PT836605E (pt) * | 1995-07-06 | 2002-07-31 | Novartis Ag | Pirrolopirimidinas e processos para a sua preparacao |
| GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| AR004010A1 (es) * | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| GB9520822D0 (en) * | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
-
1995
- 1995-04-27 GB GBGB9508538.7A patent/GB9508538D0/en active Pending
-
1996
- 1996-04-08 TW TW085104049A patent/TW436486B/zh not_active IP Right Cessation
- 1996-04-23 ES ES96910134T patent/ES2153098T3/es not_active Expired - Lifetime
- 1996-04-23 CA CA002215732A patent/CA2215732C/en not_active Expired - Lifetime
- 1996-04-23 WO PCT/GB1996/000961 patent/WO1996033980A1/en not_active Ceased
- 1996-04-23 DE DE122009000076C patent/DE122009000076I1/de active Pending
- 1996-04-23 JP JP8532252A patent/JP3040486B2/ja not_active Expired - Lifetime
- 1996-04-23 EP EP96910134A patent/EP0823900B1/en not_active Expired - Lifetime
- 1996-04-23 NZ NZ305444A patent/NZ305444A/xx not_active IP Right Cessation
- 1996-04-23 RO RO97-01978A patent/RO117849B1/ro unknown
- 1996-04-23 AU AU53433/96A patent/AU699163B2/en not_active Expired
- 1996-04-23 AT AT96910134T patent/ATE198329T1/de active
- 1996-04-23 KR KR1019970707511A patent/KR100296656B1/ko not_active Expired - Lifetime
- 1996-04-23 RU RU97119521/04A patent/RU2153495C2/ru active Protection Beyond IP Right Term
- 1996-04-23 SK SK1454-97A patent/SK282236B6/sk not_active IP Right Cessation
- 1996-04-23 BR BRPI9608082A patent/BRPI9608082B8/pt not_active IP Right Cessation
- 1996-04-23 PT PT96910134T patent/PT823900E/pt unknown
- 1996-04-23 DE DE69611361T patent/DE69611361T2/de not_active Expired - Lifetime
- 1996-04-23 DK DK96910134T patent/DK0823900T3/da active
- 1996-04-23 PL PL96323066A patent/PL189182B1/pl unknown
- 1996-04-23 EE EE9700252A patent/EE03482B1/xx active Protection Beyond IP Right Term
- 1996-04-23 SI SI9630183T patent/SI0823900T1/xx unknown
- 1996-04-23 HU HU9802839A patent/HU223313B1/hu active Protection Beyond IP Right Term
- 1996-04-23 UA UA97115677A patent/UA52602C2/uk unknown
- 1996-04-23 EG EG35896A patent/EG24134A/xx active
- 1996-04-23 CZ CZ19973396A patent/CZ288489B6/cs not_active IP Right Cessation
- 1996-04-23 CN CN96193526A patent/CN1100046C/zh not_active Expired - Lifetime
- 1996-04-24 AR ARP960102305A patent/AR003944A1/es unknown
- 1996-04-25 MY MYPI96001577A patent/MY114425A/en unknown
- 1996-04-25 HR HR960204A patent/HRP960204B1/xx not_active IP Right Cessation
- 1996-04-26 US US08/638,331 patent/US5770599A/en not_active Expired - Lifetime
- 1996-04-26 IL IL11804596A patent/IL118045A/en active Protection Beyond IP Right Term
- 1996-04-26 ZA ZA963358A patent/ZA963358B/xx unknown
-
1997
- 1997-10-24 NO NO974940A patent/NO309472B1/no not_active IP Right Cessation
- 1997-11-18 BG BG102052A patent/BG62730B1/bg unknown
-
2001
- 2001-01-11 GR GR20010400025T patent/GR3035211T3/el unknown
-
2009
- 2009-12-15 FR FR09C0065C patent/FR09C0065I2/fr active Active
- 2009-12-16 NO NO2009028C patent/NO2009028I1/no unknown
- 2009-12-17 LU LU91631C patent/LU91631I2/fr unknown
- 2009-12-17 NL NL300429C patent/NL300429I1/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO309472B1 (no) | Kinazolin-derivater, anvendelse og fremstilling derav, samt farmasöytisk preparat | |
| US5932574A (en) | Quinazoline derivatives | |
| US6015814A (en) | Quinazoline derivative | |
| US5942514A (en) | Quinazoline derivatives | |
| EP0823901B1 (en) | Quinazoline derivative | |
| US5814630A (en) | Quinazoline compounds | |
| US5770603A (en) | Quinazoline derivatives | |
| NO311936B1 (no) | Kinazolin-derivater som antitumor-midler og anvendelse derav, samt fremgangsmåte for fremstilling og farmasöytisk preparat | |
| WO1995003283A1 (en) | Quinazoline derivatives and their use as anti-cancer agents | |
| HK1005371B (en) | Quinazoline derivatives | |
| MXPA97008177A (en) | Quinazol derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: IRESSA-GEFITINIB; NAT. REG. NO/DATE: EU/1/09/526/001/NO 20090902; FIRST REG. NO/DATE: CH , 56154 20040302 Spc suppl protection certif: 2009028 Filing date: 20091216 Extension date: 20190302 Effective date: 20111007 |
|
| SPCK | Change in the validity period of an spc |
Free format text: PRODUCT NAME: GEFITINIB ELLER ET FARMASOYTISK ALSEPTABELT SALT DERAV; NAT. REG. NO/DATE: EU/1/09/526/001/NO 20090902; FIRST REG. NO/DATE: CH , 56154 20040302 Spc suppl protection certif: 2009028 Extension date: 20190302 |
|
| MK1K | Patent expired | ||
| SPCX | Expiry of an spc |
Spc suppl protection certif: 2009028 Effective date: 20190305 |